Clinical trial NCT03953612
Conditions: Cocaine-Related Disorders
Sponsor: Yale University
Start date: 2019-03-12; Completion date: 2023-05-08
Enrollment: 58 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with cocaine use disorder (CUD).

Detailed description:
This experimental study aims to examine the effects of PREG on a) repeated cocaine craving, mood and neurobiological reactivity to brief, guided imagery exposure to stress, drug cues and neutral situations in the laboratory and b) daily cocaine intake, craving, cognition and mood in men and women with CUD; and c) sex differences in all of these outcomes. The study's hypothesis is that PREG vs PLA will dose-specifically decrease stress-induced and drug-cue induced cocaine craving, improve mood and cognitive performance, and normalize hypothalamic pituitary adrenal (HPA) axis response to stress and drug-cue imagery, and reduce cocaine intake and craving in daily life in individuals with CUD.

Arms: arm 1: Eligible participants will be randomly assigned to PREG 300 mg/day over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for first two weeks and then outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient option where they will participate in the entire study outpatient at YSC. arm 2: Eligible participants will be randomly assigned to a placebo (PLA) treatment over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for the first two weeks and then transition to outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient only option where they will participate in the entire study outpatient at YSC. arm 3: Eligible participants will be randomly assigned to PREG 500 mg/day over 8 weeks with a) an inpatient-outpatient option where they will be admitted to the Clinical Neuroscience Research Unit (CNRU) at the Connecticut Mental Health Center (CMHC) for first two weeks and then outpatient at Yale Stress Center (YSC) for the remaining 6 weeks, or b) an outpatient option where they will participate in the entire study outpatient at YSC.
Interventions: intervention 1: Pregnenolone (PREG) intervention 2: Placebos
Intervention descriptions: intervention 1: 2 doses of PREG (300 or 500 mg/day) intervention 2: placebo

Protocol documents:
Prot_SAP_000.pdf: 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 1 of 55
  
YALE UNIVERSITY
                                  HUMAN INVESTIGATION COMMITTEE
                                     Application to Involve Human Subjects in Biomedical Research
100 FR1 (2015-2) 
SECTION I: ADMINISTRATIVE INFORMATION
Title of Research Project: 
The role of neuroactive steroids in stress, drug craving and drug use in cocaine use disorders
Principal Investigator:
Verica Milivojevic, PhD
Yale Academic Appointment:
Assistant Professor
Department: Psychiatry
Campus Address: 
2 Church Street South Suite 209, New Haven, CT 06519
Campus Phone: 203-737-1176
Fax: 203-737-1272
Pager: 
E-mail: verica.milivojevic@yale.edu
Protocol Correspondent Name & Address (if different than PI):
Julie Pinto, MS
Campus Phone: 203-737-5489
Fax: 203-737-1272
E-mail: julie.pinto@yale.edu
Yale Cancer Center CTO Protocol Correspondent Name & Address (if applicable):
Campus Phone: 
Fax: 
E-mail: 
Business Manager:
Campus Phone :
Fax :
E-mail
Investigator Interests:
Does the principal investigator, or do any research personnel who are responsible for the design, 
conduct or reporting of this project or any of their family members (spouse or dependent child) 
have an incentive or interest, financial or otherwise, that may affect the protection of the human 
subjects involved in this project, the scientific objectivity of the research or its integrity? Note: 
The Principal Investigator (Project Director), upon consideration of the individual’s role and 
degree of independence in carrying out the work, will determine who is responsible for the 
design, conduct, or reporting of the research. 
See Disclosures and Management of Personal Interests in Human Research 
http://www.yale.edu/hrpp/policies/index.html#COI 
  Yes
x  No
Faculty Advisor:(required if PI is a student, 
resident, fellow or other trainee)           
 NA
Rajita Sinha, PhD
Yale Academic Appointment:
Professor 
Campus Address: 
2 Church Street South Suite 209, New Haven, CT 06519
Campus Phone: 737-5805
Fax: 737-1272
Pager: 
E-mail: 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 2 of 55
Do you or does anyone on the research team who is determined by you to be responsible for the 
design, conduct or reporting of this research have any patent (sole right to make, use or sell an 
invention) or copyright (exclusive rights to an original work) interests related to this research 
protocol?
  Yes
x  No
If yes to either question above, list names of the investigator or responsible person:
The Yale University Principal Investigator, all Yale University co-investigators, and all Yale 
University individuals who are responsible for the design, conduct or reporting of research must 
have a current financial disclosure form on file with the University’s Conflict of Interest Office. 
Yale New Haven Hospital personnel who are listed as co-investigators on a protocol with a Yale 
University Principal Investigator must also have a current financial disclosure form on file with 
the University’s Conflict of Interest Office. If this has not been done, the individual(s) should 
follow this link to the COI Office Website to complete the form:  http://www.yale.edu/coi/  
NOTE: The requirement for maintaining a current disclosure form on file with the University’s 
Conflict of Interest Office extends primarily to Yale University and Yale-New Haven Hospital 
personnel.  Whether or not they are required to maintain a disclosure form with the 
University’s Conflict of Interest Office, all investigators and individuals deemed otherwise 
responsible by the PI who are listed on the protocol are required to disclose to the PI any 
interests that are specific to this protocol.
SECTION II: GENERAL INFORMATION
1. Performing Organizations:  Identify the hospital, in-patient or outpatient facility, school or 
other agency that will serve as the location of the research.  Choose all that apply:
 
a. Internal Location[s] of the Study:
 Magnetic Resonance Research Center 
 Yale University PET Center
     (MR-TAC)   
 YCCI/Church Street Research Unit (CSRU)
 Yale Cancer Center/Clinical Trials Office (CTO)    
 YCCI/Hospital Research Unit (HRU)
 Yale Cancer Center/Smilow
 YCCI/Keck Laboratories
 Yale-New Haven Hospital
 Yale-New Haven Hospital—Saint Raphael Campus
 Cancer Data Repository/Tumor Registry
 Specify Other Yale Location: Yale Stress Center, 2 Church Street South, Suite 209
b. External Location[s]:
 APT Foundation, Inc.
 Haskins Laboratories
 Connecticut Mental Health Center
 John B. Pierce Laboratory, Inc.
 Clinical Neuroscience Research Unit (CNRU) 
Veterans Affairs Hospital, West Haven
 Other Locations, Specify:
 International Research Site 
(Specify location(s)):
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 3 of 55
c. Additional Required Documents (check all that apply):
 N/A
*YCCI-Scientific and Safety Committee (YCCI-SSC)
Approval Date: 
*Pediatric Protocol Review Committee (PPRC)
Approval Date: 
*YCC Protocol Review Committee (YRC-PRC)
Approval Date:
*Dept. of Veterans Affairs, West Haven VA HSS
Approval Date: 
*Radioactive Drug Research Committee (RDRC)
Approval Date: 
 YNHH-Radiation Safety Committee (YNHH-RSC)
Approval Date: 
 Yale University RSC (YU-RSC)
Approval Date:
 Magnetic Resonance Research Center PRC (MRRC-PRC)
Approval Date:
 *Nursing Research Committee
Approval Date:
 YSM/YNHH Cancer Data Repository (CaDR)
Approval Date: 
 Dept. of Lab Medicine request for services or specimens form
 Imaging on YNHH Diagnostic Radiology equipment request form (YDRCTO request) found 
at  http://radiology.yale.edu/research/ClinTrials.aspx)
*Approval from these committees is required before final HIC approval is granted. See instructions 
for documents required for initial submission and approval of the protocol. Allow sufficient time for 
these requests. Check with the oversight body for their time requirements.
2. Probable Duration of Project: State the expected duration of the project, including all 
follow-up and data analysis activities. 
August2016- July 2024
3. Research Type/Phase: (Check all that apply)
a. Study Type
   
 Single Center Study
   
 Multi-Center Study
Does the Yale PI serve as the PI of the multi-site study? Yes 
No 
  
 Coordinating Center/Data Management
  
 Other: 
b. Study Phase
 N/A
    
 Pilot
 Phase I
 Phase II
 Phase III
 Phase IV
    
 Other (Specify) 
4. Area of Research: (Check all that apply) Note that these are overlapping definitions and 
more than one category may apply to your research protocol. Definitions for the following 
can be found  in the instructions section 4c:
 Clinical Research: Patient-Oriented
  
 Clinical Research: Outcomes and 
 Clinical Research: Epidemiologic and Behavioral 
                Health Services
 Translational Research #1 (“Bench-to-Bedside”)    
 Interdisciplinary Research
 Translational Research #2 (“Bedside-to-Community”) 
 Community-Based Research
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 4 of 55
5.   Is this study a clinical trial? Yes 
No 
NOTE the current ICMJE (International Committee of Medical Journal Editors) definition of a 
clinical trial: “any research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health outcomes.” Health-related 
interventions include any intervention used to modify a biomedical or health-related outcome (for 
example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and 
process-of-care changes). Health outcomes include any biomedical or health-related measures 
obtained in patients or participants, including pharmacokinetic measures and adverse events”
If yes, where is it registered?
Clinical Trials.gov registry 
Other (Specify) 
The study is not yet registered on clinicaltrials.gov, but we will be registering it there shortly.
Registration of clinical trials at their initiation is required by the FDA, NIH and by the ICMJE.
If this study is registered on clinicaltrials.gov, there is new language in the consent form and compound 
authorization that should be used.
For more information on registering clinical trials, including whether your trial must be 
registered, see the YCCI webpage, http://ycci.yale.edu/researchers/ors/registerstudy.aspx 
or  contact YCCI at 203.785.3482)
6. Does the Clinical Trials Agreement (CTA) require compliance with ICH GCP (E6)? 
Yes 
 No
7. Will this study have a billable service? A billable service is defined as any service rendered to 
a study subject that, if he/she was not on a study, would normally generate a bill from either 
Yale-New Haven Hospital or Yale Medical Group to the patient or the patient’s insurer. The 
service may or may not be performed by the research staff on your study, but may be provided by 
professionals within either Yale-New Haven Hospital or Yale Medical Group (examples include 
x-rays, MRIs, CT scans, specimens sent to central labs, or specimens sent to pathology). Notes: 
1. There is no distinction made whether the service is paid for by the subject or their insurance 
(Standard of Care) or by the study’s funding mechanism (Research Sponsored). 2. This generally 
includes new services or orders placed in EPIC for research subjects. 
Yes 
 No
 If answered, “yes”, this study will need to be set up in OnCore, Yale’s clinical research 
management system, for Epic to appropriately route research related charges. Please contact 
oncore.support@yale.edu
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 5 of 55
8.. Are there any procedures involved in this protocol that will be performed at YNHH or one of 
its affiliated entities?  Yes ___ No _X__  If Yes, please answer questions a through c and note 
instructions below.  If No, proceed to Section III.
a. Does your YNHH privilege delineation currently include the specific procedure that you will 
perform?
b. Will you be using any new equipment or equipment that you have not used in the past for 
this procedure?
 
c. Will a novel approach using existing equipment be applied?
 
If you answered “no” to question 8a, or "yes" to question 8b or c, please contact the YNHH 
Department of Physician Services (688-2615) for prior approval before commencing with your 
research protocol.
Please note that if this protocol includes Yale-New Haven Hospital patients, including patients at 
the HRU, the Principal Investigator and any co-investigators who are physicians or  mid-level 
practitioners (includes PAs, APRNs, psychologists and speech pathologists) who may have direct 
patient contact with patients on YNHH premises must have medical staff appointment and 
appropriate clinical privileges at YNHH. If you are uncertain whether the study personnel meet 
the criteria, please telephone the Physician Services Department at 203-688-2615. By signing 
this protocol as a PI, you attest that you and any co-investigator who may have patient contact 
has a medical staff appointment and appropriate clinical privileges at YNHH.
SECTION III: FUNDING, RESEARCH TEAM AND TRAINING
1. Funding Source: Indicate all of the funding source(s) for this study. Check all boxes that apply.
Provide information regarding the external funding source.  This information should include 
identification of the agency/sponsor, the funding mechanism (grant or contract), and whether 
the award is pending or has been awarded. Provide the M/C# and Agency name (if grant-
funded).  If the funding source associated with a protocol is “pending” at the time of the 
protocol submission to the HIC (as is the case for most NIH submissions), the PI should note 
“Pending” in the appropriate section of the protocol application, provide the M/C# and Agency 
name (if grant-funded) and further note that University (departmental) funds support the 
research (until such time that an award is made).  Funding is listed in IRES IRB.
2. Research Team:  All members of the research team are listed in IRES IRB. ALL members of 
the research team MUST complete Human Subject Protection Training (HSPT) and 
Health Insurance Portability and Accountability Act (HIPAA) Training before they may 
be listed on the protocol.  
NOTE: The HIC will remove from the protocol any personnel who have not completed required 
training. A personnel protocol amendment will need to be submitted when training is completed.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 6 of 55
SECTION IV:
 PRINCIPAL INVESTIGATOR/FACULTY ADVISOR/ DEPARTMENT CHAIR AGREEMENT
Department Chair’s Assurance Statement
Do you know of any real or apparent institutional conflict of interest (e.g., Yale ownership of a
As the principal investigator of this research project, I certify that:

The information provided in this application is complete and accurate.

I assume full responsibility for the protection of human subjects and the proper conduct of the
      research.

Subject safety will be of paramount concern, and every effort will be made to protect subjects’
      rights and welfare.

The research will be performed according to ethical principles and in compliance with all federal,
      state and local laws, as well as institutional regulations and policies regarding the protection of  
      human subjects.

All members of the research team will be kept apprised of research goals.

I will obtain approval for this research study and any subsequent revisions prior to my initiating the
      study or any change and I will obtain continuing approval of this study prior to the expiration date     
      of any approval period.

I will report to the HIC any serious injuries and/or other unanticipated problems involving risk to
      participants.

I am in compliance with the requirements set by the University and qualify to serve as the
      principal investigator of this project or have acquired the appropriate approval from the 
      Dean’s Office or Office of the Provost, or the Human Subject Protection Administrator at
      Yale-New Haven Hospital, or have a faculty advisor.

I will identify a qualified successor should I cease my role as principal investigator and facilitate a
smooth transfer of investigator responsibilities.
_____
 
PI Name (PRINT) and Signature
Date
As the faculty advisor of this research project, I certify that:

The information provided in this application is complete and accurate.

This project has scientific value and merit and that the student or trainee investigator has the necessary 
resources to complete the project and achieve the aims.

I will train the student investigator in matters of appropriate research compliance, protection of human 
subjects and proper conduct of research.

The research will be performed according to ethical principles and in compliance with all federal, state 
and local laws, as well as institutional regulations and policies regarding the protection of human subjects.

The student investigator will obtain approval for this research study and any subsequent revisions prior to 
initiating the study or revision and will obtain continuing approval prior to the expiration of any approval 
period.

The student investigator will report to the HIC any serious injuries and/or other unanticipated       
problems involving risk to participants. 

I am in compliance with the requirements set forth by the University and qualify to serve as       the faculty 
advisor of this project. 

I assume all of the roles and responsibilities of a Principal Investigator even though the student may be 
called a PI.
___________
______
_____
    Advisor Name (PRINT) and Signature
Date
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 7 of 55
sponsoring company, patents, licensure) associated with this research project?
 Yes (provide a description of that interest in a separate letter addressed to the HIC.)
 No
As Chair, do you have any real or apparent protocol-specific conflict of interest between yourself and
the sponsor of the research project, or its competitor or any interest in any intervention and/or method
tested in the project that might compromise this research project?
Yes (provide a description of that interest in a separate letter addressed to the HIC)
No
I assure the HIC that the principal investigator and all members of the research team are qualified by
education, training, licensure and/or experience to assume participation in the conduct of this research
trial. I also assure that the principal investigator has departmental support and sufficient resources to
conduct this trial appropriately.
   ____________________________
   Chair Name (PRINT) and Signature  
    
 Date
   _________________________________
   Department
YNHH Human Subjects Protection Administrator Assurance Statement
Required when the study is conducted solely at YNHH by YNHH health care providers.
As Human Subject Protection Administrator (HSPA) for YNHH, I certify that:

I have read a copy of the protocol and approve it being conducted at YNHH.

I agree to notify the IRB if I am aware of any real or apparent institutional conflict of interest.

The principal investigator of this study is qualified to serve as P.I. and has the support of the hospital 
for this research project.
  ______________________________________
    YNHH HSPA Name (PRINT) and Signature       
Date
SECTION V: RESEARCH PLAN
1. Statement of Purpose: State the scientific aim(s) of the study, or the hypotheses to be tested. 
To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the 
role of neuroactive steroids in individuals with cocaine use disorder (CUD).  The study aims to 
examine the effects of PREG on a) cocaine craving, mood and neurobiological reactivity to brief, 
guided imagery exposure to stress, drug cues and neutral situations in the laboratory and b) daily 
cocaine intake, craving, cognition and mood in men and women with CUD; and c) sex 
differences in all of these outcomes. We hypothesize that PREG vs PLA will dose-specifically 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 8 of 55
decrease stress-induced and drug-cue induced cocaine craving, improve mood and cognitive 
performance, and normalize HPA axis response to stress and drug-cue imagery, and reduce 
cocaine intake and craving in daily life in individuals with CUD. 
  
The following aims will be addressed:
Specific Aim 1: To examine the effects of PREG doses vs PLA on experimentally provoked 
cue- and stress induced craving, anxiety, emotion, cognitive flexibility and on ACTH, cortisol 
and cardiovascular arousal as compared to neutral imagery in CUD men and women.
Hypothesis 1a:  PREG will decrease stress- and drug cue-induced cocaine craving and anxiety 
responses, increase positive emotions and improve cognitive flexibility. 
Hypothesis 1b: PREG will dose-dependently normalize basal cortisol and ACTH levels, and 
stress-induced and drug cue-induced cortisol levels and cardiovascular responses.
Specific Aim 2: To examine the safety and PK/PD profile of two doses of PREG (300mg; 
500mg; bid), and matching placebo (PLA) over a 24 hour period in CUD men and women.
Hypothesis 2a: PREG doses will be safe and well tolerated.
Hypothesis 2b: PREG will dose dependently increase ALLO but not DHEA, and with favorable 
PK/PD.
Exploratory Aim 1: To explore the preliminary efficacy of 8-week PREG (300 and 500 
mg/day) vs PLA on primary outcomes of cocaine craving and negative mood symptoms, and 
secondary cocaine use outcomes.
Exploratory Aim 2: To explore sex/gender differences in each of the above aims.
2. Background: Describe the background information that led to the plan for this project. 
Provide references to support the expectation of obtaining useful scientific data.
Evidence from clinical surveys indicates that stress frequently leads to continued drug use 
and relapse (Marlatt and Gordon 1985; Bradley, Phillips et al. 1989; Wallace, 1989; Hodgins, el 
Guebaly, & Armstrong, 1995; Miller & Tonigan, 1996). Animal studies have shown that acute 
behavioral stress facilitates drug self-administration and reinstatement to drug seeking behavior 
in drug-addicted animals that have been drug-free for extended time periods (Shaham et al., 
1995). Previous work in our laboratory has shown that exposure to previous stressful experiences 
consistently increases drug craving and stress-related arousal in cocaine and alcohol dependent 
individuals (Sinha et al., 1999a; 2000; 2003a). Data also suggests that stress-induced cocaine 
craving and related HPA and autonomic arousal are predictive of cocaine relapse after inpatient 
treatment (Daughters et al., 2009; Fox et al., 2009; Sinha et al., 2003). These data suggest that 
attenuation of stress-induced cocaine craving, and their related arousal, may be a useful target in 
drug relapse prevention. 
HPA axis is largely under GABAergic control (Herman et al., 2004). Chronic drug related 
adaptations and stress are each shown to down-regulate GABA-ergic transmission (Biggio et al., 
2007) and increase neuroactive steroid levels in the brain and periphery (Purdy et al., 1991). 
Emerging evidence suggests that pregnenolone-derived neuroactive steroids may play a role in 
modulating negative reinforcement effects of drugs of abuse and also impact stress- and drug-cue 
associated relapse. Neuroactive steroids potentiate the GABA induced opening of the GABAA 
receptor chloride channel at nanomolar concentrations, and produce anxiolytic, anticonvulsant 
and hypnotic effects similar to those induced by other GABAA receptor potentiating drugs 
(Lambert et al., 2001; Majewska et al., 1986). Most notably, fluctuations in peripheral and brain 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 9 of 55
levels of the neuroactive steroid (3α,5α)-3-hydroxypregnan-20-one (a.k.a. allopregnanolone; 
ALLO) have been associated with motivational mood-related changes during pregnancy, 
menopause, and psychiatric disorders, including depression, premenstrual dysphoric disorder, 
schizophrenia and bipolar disorder (Barbaccia et al., 1996; Concas et al., 1998; Girdler et al., 
2001; Marx et al., 2006; Uzunova et al., 2006).  In addition, intraperitoneal (i.p.) injections of 
CRF and ACTH in rats increase brain and plasma levels of ALLO (Torres et al., 2001). These 
findings indicate that neuroactive steroids may play a crucial compensatory role in mediating 
homeostasis in response to stress and possibly chronic cocaine-related allostatic neuroadaptations 
(Biggio et al., 2007; Crowley and Girdler, 2014; Sarkar et al., 2011). 
Extensive research has examined the role that neuroactive steroids play in alcohol’s effects 
(Morrow et al., 1999; Morrow et al., 2001). For example, acute alcohol increases levels of 
neuroactive steroids in plasma (VanDoren et al., 2000) and brain (Sanna et al., 2004), and 
blockade of neuroactive steroid production by the 5α-reductase (5α-R) inhibitor finasteride 
attenuated acquisition of alcohol preference in mice (Ford et al., 2008). In humans, the plasma 
concentration of ALLO was increased following severe intoxication (Torres and Ortega, 2003, 
2004), but not moderate intoxication (Holdstock et al., 2006; Nyberg et al., 2005; Pierucci-Lagha 
et al., 2006). Importantly, chronic alcohol exposure reduces both plasma and brain levels of 
ALLO (Morrow et al., 2001). Clinical studies have also shown that variation in genes that 
encode neuroactive steroid synthesis enzymes was associated with alcohol dependence 
(Milivojevic et al., 2011) and subjective effects of alcohol (Milivojevic et al., 2014), which may 
modulate risk for the development of dependence. Moreover, nicotine has been found to increase 
neuroactive steroids (Porcu et al., 2003). Unlike alcohol dependence, their levels were found to 
be higher in smokers, in whom levels of ALLO positively correlated with nicotine dependence 
severity (Marx et al., 2006). 
Recent studies using the neuroactive steroid precursor PREG, found that it improved 
negative and cognitive symptoms, and functional capacity in men and women with 
schizophrenia, as compared to placebo (Marx et al., 2009; Marx et al., 2014)) and that PREG-
induced increases in ALLO levels were associated with enhanced activation of the emotion 
regulation neurocircuitry in healthy controls (Sripada et al., 2013). A randomized placebo-
controlled trial of PREG in men and women with bipolar depression improved depressive 
symptoms and showed PREG to be safe and well tolerated in all patients (Brown et al., 2014). 
Importantly, in all these studies PREG markedly increased ALLO levels, which significantly 
correlated with the outcome measures, representing a robust “precursor loading” strategy for 
ALLO enhancement (Marx et al., 2014). Although PREG use in psychiatric conditions is only 
emerging, preclinical evidence shows promise with recent reports of PREG reducing alcohol 
self-administration in alcohol-preferring rats (Besheer et al., 2010) and also reducing cannabis 
intoxication effects in mice and rats (Vallee et al., 2014). Recent evidence from our laboratory 
suggests that pregnenolone derived neuroactive steroidscould be important in a) mediating 
regulatory cognitive function in cocaine dependence (Milivojevic et al., 2014) and b) reducing 
stress and cue-induced cocaine craving, normalizing the HPA axis response to stress, and 
improving inhibitory function in cocaine dependent men and women (Milivojevic et al., 2016). 
On the basis of these data and previous preclinical research, we aim to use the neuroactive 
steroid precursor PREG as a mechanistic probe to assess the role of neuroactive steroids in a) 
stress and cue-induced craving, b) physiological and endocrine arousal as provoked by stress and 
drug-cue imagery in the laboratory, and c) cocaine use and abstinence outcomes. Importantly, we 
will also examine the effects of gender in all these outcomes. We hypothesize that PREG will 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 10 of 55
decrease stress-induced and drug cue induced cocaine craving in laboratory sessions, 
normalize HPA axis response to stress, and reduce daily cocaine intake, craving and mood 
symptoms. We have developed a laboratory-based imagery induction method that reliably 
increases cocaine craving after imagery of stressful and drug cue events in individuals with cocaine 
use disorder (Sinha et al., 1999; 2000). However, whether a neuroactive steroid suppresses stress 
and drug induced craving in individuals with cocaine use disorder has not been directly tested. In a 
sample of 60 men and women with cocaine use disorder, we will examine the effects of PREG on 
cocaine craving, subjective mood states, and neurobiological responses in personalized stressful 
imagery and drug cues imagery. All subjects will be exposed to three imagery sessions (neutral, 
stressful and drug cues) and the order of imagery conditions will be counterbalanced across 
subjects. 
We’ve selected PREG, because it is the precursor to potent neuroactive steroids, such as ALLO, 
and because it is easily available as a dietary supplement. We selected 500 mg/day dosing based on 
prior clinical trials of PREG in psychiatric patients. In an 8-week clinical trial in schizophrenia 
patients, fixed escalating dosing from 100mg to 500mg of PREG (Marx et al., 2009) was well 
tolerated. The only side effects present in the PREG group to a greater degree than the PLA group 
were two reports of mild restlessness, one report of mild muscle pain/stiffness, and one report of 
mild cold extremities. A follow-up randomized clinical trial in men and women with schizophrenia 
used escalating doses of PREG, 100mg for 2 weeks, 300mg for 2 weeks, 500mg for 4 weeks, and 
found PREG to be safe and well tolerated (Marx et al., 2014). A 12-week randomized placebo-
controlled trial of escalating doses of PREG to 400mg daily for 4 weeks in men and women with 
bipolar depression improved depressive symptoms and showed PREG to be safe and well tolerated 
in all patients (Brown et al., 2014). A recent study using an acute dose of PREG of 400mg to 
examine its effects on emotion regulation neurocircuitry (Sripada et al., 2013), also didn’t find any 
side effects.
3. Research Plan: Summarize the study design and research procedures using non-technical 
language that can be readily understood by someone outside the discipline. Be sure to 
distinguish between standard of care vs. research procedures when applicable, and 
include any flowcharts of visits specifying their individual times and lengths. Describe 
the setting in which the research will take place.
1. Study Design and Overview 
Sixty treatment-seeking individuals with CUD (30 men; 30 women) will be recruited to 
participate in this preliminary study. Participants will be recruited through flyers and 
advertisements in local newspapers and from community substance abuse treatment facilities. 
Subjects will participate in an initial screening and intake session to obtain informed consent, 
followed by physical examination and blood work to determine eligibility. Eligible 
participants will then be either a) admitted to the Clinical Neuroscience Research Unit 
(CNRU) at the CMHC (see Inpatient Consent form) or b) begin outpatient study visits at the 
Yale Stress Center (see Outpatient Consent form) and randomly assigned to 2 doses of PREG 
(300/500 mg/day) vs placebo (PLA) treatment (N=20/group) over 8 weeks. In week 2 of 
study, CUD patients will participate in a 3-day human laboratory study at the CNRU 
(Inpatient option) or Yale Stress Center (Outpatient option) where they will be exposed to 
three experimental sessions of stress, drug cue and neutral-relaxing imagery on separate days 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 11 of 55
(Fox et al.,2007; 2009; Sinha et al., 2008; 2009; 2011) Upon completion of the laboratory 
sessions, participants will be discharged from the CNRU if they participated in the inpatient 
option of the study, and continue to be seen twice-weekly at the Yale Stress Center to receive 
medication, counseling and provide urine samples for UTOX for the remainder of the 8 
weeks of study.  Women will be enrolled study in the week of the expected beginning of 
menstruation. Thus, in women study medication will be initiated and laboratory challenges 
will be completed within the early follicular phase, when endogenous sex hormone levels are 
low. Subjects will be randomized by the Connecticut Mental Health Center (CMHC) or by 
Investigational Drug Services (IDS) research pharmacist to 300mg, 500mg of PREG or PLA. 
In the Inpatient option, participants will be provided medication by CNRU nursing staff. 
Upon transition to outpatient phase of the study, medication will be dispensed by 
Investigational Drug Services (IDS) and participants will self-administer study medication on 
a twice-daily dosing schedule for the remainder of study. All Outpatient option participants 
will self-administer study medication from the onset of the study.
Subjects will begin with full respective dose of medication immediately without a taper 
schedule, as previous studies with similar doses of pregnenolone have shown no side effects 
(Marx et. al., 2009; Marx et al., 2014; Brown et al., 2014; Sripada et al., 2013). 
Participants will complete a variety of diagnostic, cognitive and psychological assessments, a 
comprehensive physical examination and blood work and will be involved in development of 
imagery scripts from personal stress, drug-related cue and neutral situations. All study 
assessments, clinical interviews, medication compliance procedures and counseling sessions will 
have the option of being completed remotely via phone or Internet, and blood draws and urine 
sample collection will be done in-person.
 In week 2, subjects will participate in an imagery/relaxation training and habituation 
session, followed by 3 laboratory sessions on consecutive days, or as close together as 
possible. Participants will be exposed to guided imagery of a personal stressful situation, a 
drug cue related situation and a neutral relaxing situation. Participants will receive one 
exposure per day, and order of imagery type will be randomly assigned across the three days. 
2.    Study Feasibility: 
The Yale Stress Center currently screens approximately 100 subjects per month. On 
average, 10 patients meet criteria for the proposed study (individuals with cocaine use 
disorder not on other medications and otherwise healthy) and will be offered participation 
in this study. Thus we anticipate that 5 patients can be enrolled into the study monthly. 
The subjects will be recruited from those responding to advertisements and flyers for 
research.
3.    General Procedures:
All participants will be screened and recruited into the study by the research assistant 
coordinator. Potential subjects will meet with the research assistant coordinator who will, 
after an initial screening over the telephone/in person, determine eligibility based on 
inclusion/exclusion criteria. The initial screening will collect basic demographic information 
and ask questions specific to the inclusion/exclusion criteria.  The initial screening will take 
approximately 20-25 minutes.  S/he will explain all study procedures and risk/benefits and 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 12 of 55
obtain informed consent. Subjects will undergo breath alcohol testing/urine toxicology 
screens at each in-person appointment to confirm self-report of cocaine use information. 
Subjects will also have the option to visit a Quest Diagnostics location to provide blood and 
urine specimens.
Inpatient/Outpatient Laboratory Sessions:
Once a subject is deemed eligible, s/he will be randomized to 300mg PREG, 500mg PREG, or  
PLA, and medication will be dispensed by the CMHC research pharmacy and/or by IDS. 
Subjects will then be exposed to three laboratory sessions of guided imagery of stress, drug cues 
and neutral-relaxing cues as close together as possible in week 2 (identified as lab DAY 1, DAY 
2, and DAY 3). In a session prior to laboratory sessions, subjects will participate in an imagery 
script development to provide descriptions of recent stressful, drug cue related and neutral 
relaxing situations to the research assistant. On the day before laboratory sessions, subjects will 
participate in a relaxation and imagery training and IV habituation session, followed by three 
laboratory sessions that include IV blood drawing. On the 2nd day of inpatient laboratory 
sessions, blood samples will be collected pre-dose (i.e., 0) and 2, 4, 6, 8, 12, 14, and 24 h after 
drug administration to determine PREG concentrations, and those of downstream NAS such as 
ALLO, DHEA and other metabolites.
Daily surveys using a Smartphone platform (MetricWire) will prompt subjects to take study 
medication, and provide responses on their cocaine use, craving, stress and mood states for the day 
(see below for detailed description).
Outpatient treatment phase:
Subjects completing the inpatient laboratory sessions of the study will then be discharged 
from the CNRU and continue to be seen at the Yale Stress Center (see below) for the remainder 
of the 8 weeks of study. All subjects will continue to self-administer 300mg/day, 500mg/day of 
PREG/PLA/day and study staff will provide weekly medication packs to subjects, which will be 
dispensed by IDS pharmacy. 
All study participants will be seen twice per week at the Yale Stress Center at 2 Church Street 
South, Suite 209 to receive once/week counseling, provide urine and receive contingency 
management for treatment attendance. Daily surveys using the smartphone platform (MetricWire) 
monitoring will prompt subjects to take study medication, and provide responses on their cocaine 
use, craving, stress and mood states for the day. Smartphone data will be collected daily. Subjects 
will be prompted at two random times in the morning and afternoon to complete a brief 1-minute 
survey of questions and a third 5-10 minute survey to be completed at night before bedtime. The 
surveys are set up with standard automated questions and prompts and subjects will use the 
smartphone key pad to answer the prompts (via MetricWire). MetricWire, developed and owned 
by MetricWire Inc., has previously been utilized in clinical and academic research and is HIPPA 
compliant. Subjects will initially complete a training session which will last up to an hour and 
30-minutes, where we will assist in installing the MetricWire app on their smartphone device. 
They will use the app to report their daily experiences throughout the study. They will be given 
instructions on how to operate the smartphone app and a guide that they may take home with 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 13 of 55
them that will outline the information covered in the training session. They will also be given 
contact information should they have any problems or questions with the smartphone app over 
the course of the study. It will be explained that all data on the app is encrypted and that the data 
is sent to a secure server where data is identified by subject id only. Subjects will also be 
informed that we will be monitoring the upload of data from the smartphone app to the secure 
server in order to verify that everything is working correctly. Subjects will be asked to use this 
app to report their mood, stress and alcohol use, once daily in the evening, for the course of the 
study. It will take approximately 10-15 minutes to complete these assessments each day.
Subjects will receive contingency management for each visit and 1 counseling session per week. 
As part of this process, participants will provide urine screens and breathalyzer samples three times 
per week. Blood draws of 15mL of whole blood each will also be done at weeks 2 or 5 and 7 of the 
study  to measure pregnenolone levels. These levels will allow staff to ensure subjects are taking 
medication as prescribed. Subjects will also have the option to visit a Quest Diagnostics location to 
provide blood and urine specimens.
Medication compliance will also be monitored through the use of riboflavin as a marker. 
Riboflavin produces a bright yellow discoloration of the urine when the medication is taken 2 to 8 
hours prior. After the first week all subjects will be taking morning and bedtimes doses of the 
medication. After this time, staff will easily be able to visually inspect the subject’s urine to 
determine whether the morning dose has been taken. 25mg of riboflavin will be added to all doses 
of pregnenolone and placebo by the pharmacist when capsules are made. Medication compliance 
will also be monitored through video Directly Observed Therapy (DOT) using the smartphone 
application eMocha. Subjects will use the eMocha app to video record themselves taking their 
medication. Research staff will log into a secure site to view the recorded videos to assess 
medication dose adherence. 
Ten mL of whole blood will be collected during physical examination to assess eligibility, and 
thirty-two mL of whole blood will be also collected from patients on the day of the first 
laboratory session ( LAB DAY 1) for the purposes of understanding genetic factors that may 
affect craving.
Individual Counseling:
Subjects will participate in once weekly standard individual drug counseling as outlined in 
the Individual Drug Counseling Manual (IDC, Mercer & Woody, 1994) during the outpatient 
phase in order to support treatment.   Each subject will be seen by a Yale Stress Center staff 
counselor with expertise in IDC who will see the patient for the clinical component of the 
outpatient research phase. The general purpose of the counseling sessions as described in the 
manual are to: (1) acquire information about important concepts and aspects of recovery from 
addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and 
recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from 
the addiction and to improve functioning. The focus of this psycho-educational approach is on 
providing patients with frequent supportive contact, introduce them to key concepts about the 
recovery approach, and develop a sense of personal responsibility for recovery.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 14 of 55
Participants will provide urines 2x/week to assess drug use, and they will receive 
contingency management for showing up on each of the thrice/weekly appointments. Primary 
outcomes measures will be cocaine use, mood, stress and craving as assessed by Metric Wire and 
urines.
After completion of the study, subjects will be referred to aftercare at the Substance Abuse 
Treatment Unit (SATU).  
Contact and collateral information will have been obtained from subjects at intake. We currently 
use procedures that make it possible to locate and re-interview more than 90% of the patients 
recruited into our treatment and laboratory research studies. Of note, in our past completed stress 
studies with cocaine dependent individuals we obtained a 92% completion rate. Our procedures 
include informing the patient of the importance of follow-up evaluations at the time of initial 
assessment, emphasizing the patient's role as a research subject, guaranteeing complete 
confidentiality of all information, obtaining permission, addresses and telephone numbers of three 
collaterals to be contacted in order to help us locate the subject, arranging for home visits and 
telephone interviews when subjects fail to keep appointments, mailing of appointment reminders 
that are followed by telephone calls, and provision of incentive payments for successful completion 
of follow-up evaluations.  All of these procedures will be incorporated into this study.  
Laboratory Sessions: 
Rationale for Use of Personalized Imagery Procedures. Emotional imagery paradigms have been 
widely used in behavioral research studies examining the pathophysiology of anxiety disorders, 
including panic disorder, obsessive compulsive disorder and PTSD (Cook, Melamed, Cuthbert, 
McNeil, & Lang, 1988; Foa & Kozak, 1986; McNeil, Vrana, Melamed, Cuthbert, & Lang, 1993; 
Pitman, Orr, Forgue, de Jong, & Claiborn, 1987; Shalev, Orr, & Pitman, 1993; Orr et al., 1998; 
Orr, Pitman, Lasko, & Herz, 1993). These procedures are known to activate the same 
physiological, subjective and behavioral components as the emotion trigger situations, thus being a 
useful clinical research procedure for inducing stress/emotional states. Similar imagery induction 
procedures have been successfully adapted by our group in previous studies to induce specific 
emotion states in normal volunteers and stress and drug cues in cocaine dependent individuals 
(Sinha, Lovallo, & Parsons, 1992; Sinha & Parsons, 1996; Sinha, Catapano, & O'Malley, 1999a;). 
Imagery procedures have also been used in the drug abuse literature to induce drug cue-
induced drug craving and stress/negative mood induced drug craving in the laboratory (Cepeda-
Benito & Tiffany, 1996; Drobes & Tiffany, 1997; Maude-Griffin & Tiffany, 1996; Tiffany & 
Drobes, 1990; Cooney, Litt, Morse, & Bauer, 1997; Tiffany & Hakenewerth, 1991; Payne, 
Rychtarik, Rappaport, & Smith, 1992; Rubonis et al., 1994; Sinha et al., 1999a). Tiffany and 
colleagues compared imagery induction vs. in-vivo exposure to cues, and found that while both 
methods were equally effective in eliciting high levels of self-reported craving, physiological 
reactivity was greater with the imagery manipulation. Furthermore, our previous work in cocaine 
dependent individuals showing activation of the HPA axis and increases in plasma catecholamines 
with stress and with drug cue imagery indicates that the method is effective in inducing drug 
craving and in activating brain stress circuits (Sinha et al., 1999a). Thus, the imagery procedure 
includes the following distinctive components based on prior experience: 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 15 of 55
(i) Personal stressful, drug cue and neutral situations rather than standard situations will be 
selected because personal events show greater physiological reactivity and generate more intense 
emotional reactions than imagery of standardized non-personal emotions (Cook et al., 1988; McNeil 
et al., 1993; Miller et al., 1987). 
(ii) Based on Lang's network theory on emotion processing and Tiffany’s cognitive model 
of drug use and urges (Tiffany, 1990; Tiffany & Drobes, 1990) and our previous work, the addition 
of physiological, subjective and behavioral response descriptors are included in the imagery script 
so as to produce stronger activation of the experience. 
(iii) To minimize subject variability in the imagery induction procedure, we include an 
imagery training session, in which each subject receives training on how to generate and maintain a 
mental image for 2-3 minutes. The imagery training procedures have been extensively used in 
previous studies by Lang and his colleagues and by the PI in her previous work on emotions and 
stress work with cocaine abusing samples.
 
Imagery Script Development Session: In a session prior to the laboratory sessions, scripts 
for the guided imagery induction will be developed. The stress imagery script will be based on 
subjects’ description of a recent personal stressful event that they had experienced as "most 
stressful". “Most stressful” is determined by having the subjects rate the perceived stress 
experienced by them on a 10-point Likert scale where “1=not at all stressful” and “10=the most 
stress they felt recently in their life”. Only situations rated as 8 or above on this scale are accepted as 
appropriate for script development. Stressful situations that involved drug-related stimuli, such as 
being arrested for possession of drugs or being caught in a police chase, are not allowed. Examples 
of acceptable stressful situations include breakup with significant other, a verbal argument with a 
significant other or family member or unemployment-related stress, such as being fired or laid off 
from work. As stressful situations often occur in the context of cocaine use, these situations are 
thought to be associated with drug use and therefore elicit cocaine craving.  
The drug-related script will be developed by having subjects identify a recent situation that 
included drug-related stimuli and served as a trigger for subsequent cocaine use (e.g. buying crack, 
being at a bar and watching others use drugs/get high; getting together with drug using buddies). 
Drug-related situations that occurred in the context of negative affect or psychological distress will 
not be allowed, i.e., going to a bar after a marital conflict, or feeling depressed and calling a drug 
using buddy.  A neutral-relaxing script will be developed from the subjects’ commonly 
experienced neutral-relaxing situations. Neutral-relaxing events that involve drug cues will not be 
allowed.  A ‘script’ or description of each situation will be developed using Scene Development 
Questionnaires which obtain specific stimulus and response details, including specific physical and 
interpersonal context details, verbal/cognitive attributions regarding the people involved, and 
physiological and bodily sensations experienced for the situation being described. The three scripts 
for each subject will then be recorded on an audio-tape for guided imagery in the laboratory 
sessions. The order of stress, neutral and drug cue scripts will be assigned randomly, and 
counterbalanced across subjects. Detailed procedures are outlined in the Imagery Development 
Procedures Manual (Sinha, 2001b).
Manipulation Check for Script Development: All three scripts will be rated on a Likert scale 
from 1 to 10 on a standard rating form (Independent Rating Scale) by two objective independent 
raters for stressful and emotional content. If a script scores below a rating of 8 for stressful content 
on a five-point rating scale the subject will be asked to develop a new script at the next appointment 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 16 of 55
prior to the laboratory sessions. These procedures ensure that the stress and drug cue scripts of all 
subjects are equated in intensity and content. It further ensures that differences in stress reactivity 
are not due to differences in intensity and emotional content of the stressor. The procedures for 
development of imagery scripts, rating of scripts for content and physiological activation are similar 
to those used by Miller et al. (Miller et al., 1987) and have been successfully used in our previous 
work on emotions (Sinha et al., 1992; Sinha & Parsons, 1996) and on stress reactivity with cocaine 
dependent individuals (Sinha et al., 1999a). 
Imagery and Relaxation Training and IV Habituation Day. On the afternoon of the day 
before laboratory sessions, an indwelling intravenous (IV)  catheter will be inserted in the subject’s 
arm so that subjects can habituate to the stress of an IV insertion. We have found that this period of 
adaptation is critical for stable baseline measurements on testing days. No blood will be drawn on 
the training day. After insertion of IV catheter, the subject will be provided with relaxation training 
followed by general imagery and physiological response training, as described in the imagery 
training procedures manual (Lang, Levin, Miller, & Kozak, 1983). The imagery training involves 
subjects' visualizing some commonplace scenes as they are presented to them. The scenes are 
neutral and non-emotional in content, such as reading a popular magazine. Following the imagery, 
the subject is asked questions about the visualization and given pointers regarding the process of 
imagining the scene. The subject also imagines scenes that are non-emotional but physically 
arousing in nature, such as doing sit-ups in gym class. With these scenes subjects are asked whether 
they notice any changes in their physiological response, such as change in heart rate or change in 
breathing. Once again, pointers with regard to imagining the situation "as if" they were really 
present in the situation are presented. This session takes approximately one hour and was developed 
to ensure that all subjects are trained on the method of generating an image and maintaining it for 2-
3 minutes. At the end of training, the IV catheter will be removed.
Laboratory Sessions.  In week 2 of the study PREG doses/PLA administration, subjects will 
be brought into the research testing rooms of the CNRU at 2:00 PM.  The subject will then be 
prepared for physiological assessments.  An indwelling intravenous (IV) catheter will be inserted by 
the research nurse specialist in the antecubital region of the subject's non-preferred arm for blood 
sampling. Blood samples will be obtained periodically for assessment of neuroactive steroids, 
ACTH, cortisol, prolactin, NE and EPI levels. A blood pressure cuff will be placed on the subject's 
preferred arm to monitor blood pressure (BP) periodically. On-line assessment of physiological 
measures will be obtained at specified time periods during the laboratory sessions. Self-reports of 
emotional state, anxiety and cocaine craving will also be assessed periodically.
 
After preparation of assessments and a 40 minute adaptation period, two blood draws before 
imagery will be conducted (BASELINE). After the second blood draw, a 5-minute baseline period 
will follow to assess continuous pulse rate and BP assessments. Following the baseline period, 
instructions for conducting imagery will be provided. The order and content of the imagery 
condition will not be revealed to the subject or to the research staff conducting the sessions. In the 
imagery task the subjects will be asked to imagine the situation being described vividly, 'as if' it 
were happening right now”, until asked to stop. The imagery script will be played to the subject 
over headphones and the subject will be required to imagine the situation for 5 minutes. A tape 
recording for each subject's script will be developed prior to the testing situation and recorded by the 
same person for each subject. Immediately following imagery, a blood draw will be conducted 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 17 of 55
(IMAGERY). Thereafter, five recovery blood draws will be conducted at 15 minute intervals 
(RECOVERY). Timeline for assessments is detailed in Table 1. 
TABLE 1: Schedule for Laboratory Sessions
TRAINING DAY: Imagery and Relaxation and Habituation Session (1 hour)
LAB DAY 1, 2 and 3:   
IMAGERY SESSIONS
2:00 PM
            Set-up for plasma (IV insert) measures; physiological setup - HR, BP
2:10 PM
            Stabilization and Adaptation period, BP reading
2:40 PM (-20)       Initial Blood Draw (15mL), craving/DES ratings, physiological assessments
2:50 (-10)             BASELINE Period; on-line physiological recordings
2:55 (-5) 
            Baseline blood draw (15mL); craving/DES ratings, BP assessments
3:00 
            IMAGERY Period (Stress/Drug Cues/Neutral); physiological assessments
3:05 (0)
           Post-Image blood draw (15mL); craving/DES ratings; Imagery Vividness 
ratings 
3:10 (+5)             RECOVERY Period; 5-min physiological assessments; craving/DES ratings;
3:20 (+15)
Recovery1: Blood draws (15mL), craving/DES ratings; physiological 
assessments 
3:35 (+30)             Recovery2: Blood draws (15mL), craving/DES ratings; physiological 
assessments
3:50 (+45)             Recovery3: Blood draws (15mL), craving/DES ratings; physiological 
assessments
4:05 (+60) Recovery4: Blood draws (15mL), craving/DES ratings; 
4:20 (+75) Recovery5: Blood draws (15mL), craving/DES ratings; physiological assessments
4:30 PM
Relaxation tape; assess physiological levels and subjective state for return to 
baseline
15 ml of whole blood will be collected at each time point (total of 360 mls over 3 days). 
Relaxation instructions will be provided to ameliorate any residual effects of imagining 
personal stressful and drug cue situations. Subjects will then be free to leave the testing room 
and eat breakfast on the unit. Relaxation instructions have been found to be effective in reducing 
drug cue-induced craving (Margolin, Avants, & Kosten, 1994; Sinha et al., 1999a) in the 
laboratory and we will use these instructions to reduce any residual cocaine craving. After 
completion of laboratory phase, all subjects will continue to twice/weekly in outpatient 
counseling. Previous research and our clinical research experience indicates that laboratory 
induced drug craving returns to baseline after the laboratory sessions with little impact after 
laboratory exposure. 
Laboratory Assessments.
a. Self-Reports   (a) Differential Emotion Scale (DES; 246). Subjects will be asked to rate their 
current emotional state for the following: anger, fear, sadness, anxiety, joy, neutral-relaxed 
feelings. These ratings will be conducted for each assessment period during the imagery session 
(as indicated in Table 1). An abbreviated version of the DES (Izard, 1972) includes five 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 18 of 55
adjectives (a total of 30 items) are used to describe each affect state and subjects are required to 
rate on a 5-point scale the extent to which each word describes the way she feels at the present 
time. The DES has been used in human laboratory studies to assess subjective states after 
induction of moods either via imagery or other standard tasks such as mental arithmetic, Stroop 
test or in a confederate situation (Schwartz & Weinberger, 1980; Schwartz, Weinberger, & 
Singer, 1981). It has provided useful emotion state data for cocaine dependent individuals during 
stress exposure and in drug craving (Sinha et al., 1999a; Sinha, Fuse, Aubin, & O'Malley, 2000; 
Sinha et al., 2002a; a copy of the abbreviated DES is provided in Appendix A2.3).  (b) Cocaine 
Craving. Cocaine craving will be measured using an adapted brief 10-item version of the 
Cocaine Craving Questionnaire-NOW (CCQ- Tiffany, Singleton et al., 1993, ). The brief 10-item 
version of the CCQ-NOW scale has been adapted for use in the laboratory studies and has a 
reliability of .92 (Tiffany, personal communication). (c) Alcohol Craving: All subjects will be 
asked to rate alcohol craving during the laboratory sessions at time-points specified in Table 3. 
Alcohol craving will be measured using the Alcohol Urge Questionnaire (AUQ) (Bohn, Krahn et 
al., 1995), which is a brief 8-item self-report craving scale, and is designed so that it can be used 
in laboratory studies that require repeated assessments of alcohol craving such as in cue-
reactivity studies. The AUQ has high test-retest reliability (0.84) and was found to be a valid 
measure of alcohol urges that was significantly associated with drinking measures and 
dependence severity. We have previously used the AUQ in our laboratory study assessing the 
effects of naltrexone on craving and ad-lib drinking in alcoholics (O'Malley, Krishnan-Sarin et 
al, 2002).
 
b. Physiological Measures. A pulse sensor will be attached to the subject’s forefinger to obtain 
a measure of pulse rate. Blood pressure will be measured using the IBS dynamap. 
c. HPA Measures. To assess plasma levels of ACTH and cortisol, , 5ml of plasma (15 ml of 
whole blood) will be collected at each time point (total of 360 mls over 3 days). An additional 6 
blood samples of 15 ml of whole blood will be collected over 24 hours after LAB DAY 2, 
totaling an additional 90 ml of whole blood. The total amount of blood to be drawn is within 
HHS guidelines of 550 ml within 8 research weeks. The samples will be split into five 
heparinized tubes (.15 ul of heparin) and the tubes will be placed on ice immediately after blood 
drawing. Within 30 minutes of collection, the blood will be centrifuged at 4C and the serum 
removed into separate test tubes, 1 ml of plasma each for ACTH, cortisol, prolactin, NE and EPI. 
Similar blood drawing procedures have been established successfully at the Yale Stress Center in 
our previous studies with cocaine dependent individuals. Analysis of HPA measures will be 
conducted at the YCCI. ACTH  and cortisol will be measured using standard radioimmunoassay 
procedures.  
In addition, saliva samples will be collected at the same time points as the plasma samples. 
Saliva samples will be processed at the Yale HRU Core Laboratories.  This will be done to 
compare salivary cortisol measurements with the plasma cortisol assessments.
d. Neuroactive Steroid Measures. To assess plasma levels of pregnenolone, allopregnanolone 
and androstanediol, a 1mL of plasma will be collected at each timepoint, and processed as per 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 19 of 55
above. Analysis of these neuroactive steroids will be conducted at The Chemical Instrumentation 
Center at Yale, which has a state of the art gas chromatography/ mass spectrometry (GC/MS) 
instrumentation (Agilent 5973 GC-MS w/autosampler, HP 5971A GC-MS) following procedures 
outlined in Milivojevic et al., 2016).
Assessments: A trained research assistant will meet with the client at various time-points to 
assess the client on selected substance use and psychological functioning measures using 
structured interviews, self-report assessments and to obtain urine samples (at the Yale Stress 
Center) for toxicology screens. Please note that all assessments will be able to be done remotely 
via phone or Internet, using the Redcap platform which contains all the study assessments.A 
description of the assessment battery follows.
Screening Assessments:
Assessment of IQ and Executive Functioning. The Shipley Institute of Living Scale (Shipley 
1940) is a paper and pencil test taking about 15-20 minutes to complete. It consists of two 
parts (vocabulary and abstraction) which when combined provides a global measure of 
cognitive functioning and IQ. The Shipley will be administered to ensure that subjects will be 
able to successfully participate in the self-report components and comprehend all aspects of 
the protocol.
Sociodemographic/general patient information.  Demographic data, medical history, and 
family psychiatric history will be assessed with interviews and self-report forms that provide 
data on age, race, socioeconomic status, marital status, psychiatric family history, educational 
and occupational levels, and significant medical history.
The Structured Clinical Interview for DSM-V (SCID, First et al., 1995) will be used to obtain 
DSM-V cocaine and other substance use disorder diagnoses. The SCID's reliability and 
validity among substance-using populations has been established in large-scale surveys 
(Kranzler et al., 1996). The number of dependence syndrome elements endorsed from the 
DSM-V substance abuse/dependence criteria will assess severity of cocaine and other drug 
use disorder. The SCID will also be used to obtain previous psychiatric diagnoses. 
Medical History and Physical Examination: All patients will be required to participate in a 
physical examination including a medical history, electrocardiogram (EKG), blood, and urine 
laboratory assessments prior to initiation of PREG/PLA to ensure eligibility for pregnenolone 
study protocol. Female patients will also have a urine pregnancy test. These tests will be 
conducted at the Yale Stress Center under Dr. Gretchen Hermes’ supervision. Subjects will 
also have the option to visit a Quest Diagnostics location to provide blood and urine 
specimens.
The California Psychological Inventory (CPI-So) (Gough, 1951) is the socialization scale of 
the CPI personality test used to assess the degree of social maturity, integrity, and rectitude 
that the individual has attained.
The Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Profile is a 
NIH developed patient reported outcome  measurement tool that measures physical 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 20 of 55
functioning, anxiety, depression, fatigue, sleep disturbance, social role participation and pain, 
that have a major impact on quality-of-life across a variety of chronic diseases.
Drug Use Measures: 
The Alcohol Urge Questionnaire (AUQ) is a brief 8-item self-report craving scale used to 
measure alcohol craving. The AUQ will be given weekly and at follow-up interviews.
The Addiction Severity Index (ASI: McLellan et al., 1992) is a structured interview that 
assesses the severity of substance use and substance-related problems in the areas of medical, 
employment, legal, family/social and psychiatric functioning. The ASI is the most widely 
used instrument for assessment of substance use and related problems and its psychometric 
properties are well-established (Cacciola et al., 1997).  The ASI will be used at pre-treatment 
and week 8. Follow-up ASI interviews will be conducted at 30 days post-treatment. 
The Substance Use Calendar was developed by Miller and DelBoca (1994) and is based on 
the Time-Line Follow-Back Method (TLFB) (Sobell, Maisto et al. 1980). The SUC uses a 
calendar prompt and a number of other memory aids (e.g., holiday, payday, and other 
personally relevant dates) to facilitate accurate recall of daily drug use during the targeted 
period.  It has demonstrated adequate levels of reliability and validity when administered as 
an in-person interview, over the telephone, and when administered via computer (e.g. Carey, 
1997; Sobell, Brown, Leo, & Sobell, 1996; Sobell, Sobell, Leo & Cancilla, 1988). It’s 
reliability and validity in drug abusing samples has also been established (Fals-Stewart, et al., 
2000). In the current study we will use to obtain self-report of day to day use of cocaine, and 
other drugs, for the 60 days prior to treatment, weekly during treatment and at the 30 day 
follow-up interviews.
The Smoking History Questionnaire will be given to collect information on current and past 
smoking habits. The questionnaire also questions the subject’s number of past quit attempts, 
their perception of health risks, and perceived barriers to quitting.
Fagerstrom Test for Nicotine Dependence (FTND: Fagerstrom, 1978) is a 6-item 
questionnaire for assessing tobacco dependence, which evaluates, among other factors, depth 
of inhalation, time from awakening to day's first cigarette, and difficulty in smoking 
cessation.
The Alcohol Use Disorders Identification Test (AUDIT) (Bohn et al., 1995) is a 10-item 
screening tool developed by the World Health Organization (WHO) to assess alcohol 
consumption, drinking behaviors, and alcohol-related problems.
Alcohol Dependence Scale (ADS) is a 25 item to measure severity of alcohol dependence.
Abstinence Measures:
Cocaine Selective Severity Assessment (CSSA) is an 18-item scale that measures the cocaine 
withdrawal signs and symptoms within the past 24 hours. The CSSA will be used weekly and 
at the follow-up interview. 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 21 of 55
Clinical Institute Withdrawal Assessment (CIWA) is a 13 item scale that measures alcohol 
withdrawal signs and symptoms.  The assessment will be administered weekly and at follow-
up interviews.
Urine Toxicology and Breathalyzer Screening: A urine toxicology screen will be conducted 
at intake to confirm cocaine, alcohol, and nicotine use. During treatment, urines will be 
collected 2 times weekly to confirm sobriety In addition, urine samples will be taken weekly 
during outpatient treatment and at follow-up appointment using on-site TESTCUP5 Drug 
Screen (Roche Diagnostics Inc., Totowa, NJ) to monitor opiate and other drug use. The 
TestCup5 kit provides results for opioids, cocaine, THC, PCP and barbiturates. Continine 
levels in the urine will also be measured. Breath alcohol levels will also be assessed with the 
Alcosensor III Intoximeter, and carbon monoxide levels with a carbon monoxide 
breathalyzer, at each face-to-face contact, 2 times weekly. 
Cocaine Craving Questionnaire (CCQ) is a 10-item self-report questionnaire that measures 
current craving state. This self-report will be completed weekly throughout the study.
The Treatment Review Scale (TRS), an adapted version of the Treatment Services Review 
(TSR) (McLellan, Kushner et al. 1992) will be administered weekly during treatment to 
assess participation in self-help. The Questionnaire on Smoking Urges (QSU (brief) is a 10-
item self-report measure designed to assess urges and cravings to smoke, with higher scores 
indicating stronger urges. Subjects will complete the questionnaire weekly and at follow-up 
interviews.
Thought About Abstinence Scale (TAAS) (Hall et al, 1990) is a four-item scale used to assess 
motivation to quit and abstinence self-efficacy.
Assessment of Psychological Symptoms: 
A number of self- report measures of psychological functioning will be obtained weekly to 
examine pregnenolone’s effects on psychological functioning. The following well-
established and reliable instruments will be used: 
The Emotion Regulation Scale (ERS) (DERS) is a 36-item questionnaire to provide a 
comprehensive measure of the difficulties in emotion regulation. 
The Hospital Anxiety and Depression Scale (HADS; Zigmond and Snaith, 1983) is a 7 item, 
brief measure of generalized symptoms of anxiety and fear. Respondents indicate how they 
currently feel and responses are rated on a 4-point Likert scale and range from 0 to 3.
Obsessive Compulsive Drinking Scale (OCDS) is a 14 item test to measure obsessionality 
and compulsion.
The Barratt Impulsiveness Scale, Version 11 (BIS-11; Patton et al., 1995) is a 30 item self-
report questionnaire designed to assess general impulsiveness. The structure of the 
instrument allows for the assessment of six first-order factors (attention, motor, self-control, 
cognitive complexity, perseverance, cognitive instability) and three second-order factors 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 22 of 55
(attentional impulsiveness [attention and cognitive instability], motor impulsiveness [motor 
and perseverance], nonplanning impulsiveness [self-control and cognitive complexity]). 
The Life Orientation Test (LOT-R) (Scheier and Carver (1985) is a scale containing eight 
items that measures an individual’s level of optimism.
The Brief Self-Control Survey (SCS) (Tangney et al., 2004) measures an individual’s 
perceived ability to exercise his/her self-control in a variety of domains, including self-
discipline, deliberate/nonimpulsive action, healthy habits, work ethic, and reliability. 
Stress-Related Assessments: 
The Chronic Stress Checklist is adapted from Turner’s (1995) widely used Checklist 
Measures of Stressful Life Events. It will be used to assess for both chronic and recent life 
stress.
Perceived Stress Scale (PSS; Cohen et al., 1983) assesses the degree to which situations are 
appraised as threatening or otherwise demanding and that there are insufficient resources to 
cope with the situation. This global measure of perceived stress has been widely used in the 
behavioral medicine literature to examine the effects of stress on disease and treatment 
outcome. The PSS is a 14 item self-report measure with adequate reliability and both 
predictive and construct validity. It has been shown to predict smoking reduction in a 
smoking cessation treatment program (Cohen et al., 1983; Cohen & Lichtenstein, 1990). It 
will be used to assess stress levels weekly in study patients during treatment and at the 
follow-up appointment (copy included in Appendix B). 
The COPE Questionnaire (Carver, Scheier et al. 1989) is a multidimensional coping 
inventory that assesses the different ways in which people respond to stress. It is a 53-item 
self-report measure that assesses 14 coping strategies categorized into three coping styles 
(Problem Focused Coping; Emotion Focused Coping; Less-Useful Coping). While most 
previously developed coping scales have lacked good empirical validation, the COPE 
questionnaire has been developed with good overall reliability and construct validity, and is 
judged as an adequate measure of coping strategies (Parker & Endler, 1992). In this study we 
will assess stress-related coping at baseline and once during treatment and at the follow-up to 
assess effects of study medication on stress-related coping. 
Cognitive assessments
The NIH Tool Box Battery will be administered at baseline (first week of study enrollment) 
and again at some point during pregnenolone treatment. The battery includes cognitive tests 
of executive function
Stroop Color Word Test (Golden, 1976). On the initial trial participants are given 45 seconds 
to read as quickly as possible a list of 100 color words (red, green, blue) randomly arranged 
and printed in black ink. On the second trial participants have 45 seconds to identify as 
quickly as possible the color of 100 “XXXX” printed in either red, green or blue ink. The 
final trial consists of the 100 words presented in the initial trial in the colors presented in the 
second trial. In all cases, the word (i.e. red) is different from the color it is printed in (i.e. 
blue. (e.g. “red”). Subjects are given 45 seconds to name the color of the ink as quickly as 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 23 of 55
possible. The number of raw items read for each trial is recorded and converted to 
standardized T scores. (5 mins)
Safety and Side Effects Measures  
The following safety measures will be assessed at each contact with the patient: 
Sitting vital signs: including heart rate, systolic and diastolic blood pressure will be assessed 
every 15-30 minutes for one hour 2x weekly throughout study. Laboratory chemistry will be 
assessed at week 3, 5 and week 6 after initial assessment for abnormal values. 
A Systematic Assessment of Treatment Emergent Events (SAFTEE) will be assessed at each 
visit to assess any adverse events of side effects that may have occurred in patients during the 
treatment study. The scale will assess physical or health problems since the last visit, 
including changes in physical appearance and changes in functioning due to physical 
condition . If the subject describes any changes a detailed assessed of the symptom or 
complaint will be conducted using the SAFTEE form pages 2-4. An adverse events form 
developed by our group will be completed for the event according to the criteria outlined in 
the Data Safety Monitoring Plan in the Human Subjects section. Thus, study staff and 
investigators will evaluate all adverse events, and an adverse event report will be completed 
and the Yale HIC, CMHC and IDS pharmacy will be notified (see Data Safety Monitoring 
Plan for procedures for safety monitoring and reporting of adverse events). Adverse 
events/side effects will be assessed weekly throughout the study.   
Other Relevant Measures: 
QMI Vividness of Imagery Scale (Sheehan, 1967) will be used to assess the vividness of 
mental imagery. The 35 items of the QMI are statements regarding the imagery ability in 
seven different sensory modalities (visual, auditory, olfactory, cutaneous, kinaesthetic, 
gustatory, and organic). Subjects are asked to rate their imagery vividness on a 7-point scale 
(1 = I perceive it perfectly clearly, as if it were real; 7 = I think about it, but I cannot imagine 
it). A low score on the QMI indicates more vivid imagery.
The Menstrual Cycle Questionnaire (MCQ) is a 30-item standardized instrument including 
23 questions about symptoms experienced during a typical menstrual cycle and questions 
regarding typical cycle and period length. Female subjects will complete the questionnaire at 
baseline.
4. Genetic Testing   N/A 
A. Describe
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 24 of 55
i.
the types of future research to be conducted using the materials, specifying if 
immortalization of cell lines, whole exome or genome sequencing, genome wide 
association studies, or animal studies are planned
The samples will be used to examine specific genes, by group analysis.
ii. the plan for the collection of material or the conditions under which material will 
be received
The genetic testing materials will be extracted from whole blood, which will be collected in the 
study (on LAB DAY 1).
iii. the types of information about the donor/individual contributors that will be 
entered into a database
The data base will only have group coding. Samples will be identified by study ID only, and no 
information about the individual donors will be entered.
iv. the methods to uphold confidentiality
Samples will be marked only by study ID numbers and no other personal identifying information 
will be sent to the laboratory. Once genetic analysis is conducted the data will be sent back to our 
laboratory and the genetic data will be stored in computerized research records that will then be 
analyzed by group analysis. There is no plan to return specimens back. If the subject chooses to 
withdraw their sample, the subject will be informed that the genetic blood sample will be 
stripped of all identifiers (anonymized) including study id number and we will continue to use 
the samples .
B. What are the conditions or procedures for sharing of materials and/or distributing for 
future research projects?
At this point in time, there are no plans for sharing of materials or distributing for future 
research projects. Should this occasion arise, all specimens will be stripped of all identifiers, 
including the study ID number. 
C. Is widespread sharing of materials planned?  See above
D. When and under what conditions will materials be stripped of all identifiers?  See above
E. If the subject chooses to withdraw their sample, the subject will be informed that the 
genetic blood sample will be stripped of all identifiers (anonymized) including study id 
number. Can donor-subjects withdraw their materials at any time, and/or withdraw the 
identifiers that connect them to their materials?
Yes, the subject can withdraw the identifiers that connect them to their materials.
How will requests to withdraw materials be handled (e.g., material no longer identified: that is, 
anonymized) or material destroyed)?
The genetic blood sample will be stripped of all identifiers (anonymized) including study id 
number.
F. Describe the provisions for protection of participant privacy
Samples will be marked only by study ID numbers and no other personal identifying information 
will be sent to the laboratory. Once genetic analysis is conducted the data will be sent back to our 
laboratory and the genetic data will be stored in computerized research records that will then be 
analyzed by group analysis.
G. Describe the methods for the security of storage and sharing of materials 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 25 of 55
Upon enrollment, all study subjects will be assigned a unique study number. The study number—
and no personal identifiers—will be used as labels for study records, samples and any other related 
research documentation. All electronic and digital files will be stored on the secure Yale network, 
and the PC accessing the network will be password protected and encrypted. All paper files, such 
as consent forms, will be stored in a locked file cabinet in a locked office and access is limited to 
members of the study research team.
Genetic and Gene-Expression Measures.
Thirty-two mL of whole blood will be collected from patients on day 1 of the laboratory 
sessions, separately from the blood draws during the lab sessions, for the purposes of 
understanding genetic factors that may influence the way in which the subject behaves/feels. 
 
Microarray profiling will be used to detect these molecular changes by comparing the 
molecular profile of the blood drawn during the physical to blood samples drawn on day 1 of 
the laboratory sessions. Total RNA will be isolated from whole blood collected at the 
indicated times using the PAXgene Blood RNA Isolation kit (QIAGEN, Valencia, CA) per 
the manufacturer's instructions. Total RNA will be depleted of globin mRNA message using 
GLOBINclear hybridization capture technology (Ambion, Austin, TX). Globin-reduced total 
RNA will then be used to carry out cDNA synthesis and overnight in vitro transcription 
utilizing the Illumina TotalPrep RNA Amplification Kit (Ambion).  Biotinylated cRNA (1.5 
µg) will be hybridized onto an Illumina Sentrix Beadchip (Human-6v2). This platform was 
chosen because of its lower cost in relation to Affymetrix GeneChips and demonstrated 
utility in detecting expression changes in RNA samples derived from whole blood (Barnes et 
al., 2005). Hybridizations and array scanning will be carried out at the Yale Neuroscience 
Microarray Center.
Optional Specimens for Future Storage/Genetic Testing
Specimens will be stored for an unlimited time, and may be used to make a cell line that will live 
indefinitely.  Future research may look at these genes, which are the units of inheritance that are 
passed down from generation to generation. Future genetic analysis may possibly include finding 
out the details of how DNA is put together, such as whole exome or genome sequencing, or 
genome wide association studies (that is, looking at genes other than those associated with a 
specific disease).  All samples and information will receive a unique code.  Other researchers 
will only receive coded samples and information, and will not be able to link the code to a 
participant.  Strict security safeguards are in place to reduce the chance of misuse or unplanned 
release of information.
No additional blood will be collected, only the 32ml genetic bloods.
Specimens/data will not be shared with NIH(NIH) Genome-Wide Association Studies (GWAS) 
repository
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 26 of 55
5. Subject Population: Provide a detailed description of the types of human subjects who will 
be recruited into this study.
Sixty individuals with cocaine use disorder (30 men; 30 women) will be recruited to 
participate in this study.  Subjects will be recruited from the community without regard to 
sex, racial, or ethnic background.  We expect a representative sample will be drawn from the 
community.
6. Subject classification: Check off all classifications of subjects that will be specifically 
recruited for enrollment in the research project. Will subjects who may require additional 
safeguards or other considerations be enrolled in the study? If so, identify the population of 
subjects requiring special safeguards and provide a justification for their involvement.
 Children
 Healthy 
Fetal material, placenta, or dead fetus
 Non-English Speaking
 Prisoners
 Economically disadvantaged persons
 Decisionally Impaired
 Employees
 Pregnant women and/or fetuses
 Yale Students 
Females of childbearing potential
NOTE: Is this research proposal designed to enroll children who are wards of the state as 
potential subjects? 
 Yes  
 No (If yes, see Instructions section VII #4 for further 
requirements)
7. Inclusion/Exclusion Criteria: What are the criteria used to determine subject inclusion or    
exclusion?
A. Human Subjects Involvement, Characteristics and Design
Sixty participants who meet current DSM-V criteria for cocaine use disorder will be recruited 
to participate in this study.  Women will be included in subject sample, and will represent 
50% of the study sample in order to explore gender effects. The CUD individuals recruited 
into our previous studies have tended to be of the following racial and ethnic background: 
35% are Caucasian, 60% are African-American, 5% are Hispanic. As a result, we expect that 
the projected demographics of our sample will follow the above gender and race breakdown. 
The following inclusion and exclusion criteria will be followed:
Inclusion Criteria:
i.
Male or female individuals, ages 18 to 65.
ii. Subjects must meet current DSM-V criteria for cocaine use disorder; documented 
positive urine toxicology screen for cocaine at intake or collateral information from family 
members, significant others, room-mates etc., on recent use.
iii. Subject has voluntarily given informed consent and signed the informed consent 
document.
iv.     Able to read English and complete study evaluations. 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 27 of 55
Exclusion Criteria:
i.
Women who are pregnant, or nursing or are of childbearing potential and not practicing an 
effective means of birth control.
ii. Meet current severe criteria for use disorder on another psychoactive substance, such as 
amphetamines, hallucinogens/PCP, excluding nicotine.
iii. Meet current criteria for an opiate use disorder.
iv. Current use of any psychoactive drugs, including naltrexone and antabuse, excluding stable 
use of SSRIs, SNRIs, and benzodiazepines. 
v. Any psychotic disorder or current Axis I psychiatric symptoms requiring specific 
attention, excluding stable use of SSRIs, SNRIs, and benzodiazepines. 
vi. Significant underlying medical conditions such as breast cancer, prostate cancer, and history 
of seizures, cerebral, renal, thyroid or cardiac pathology which in the opinion of study 
physician would preclude patient from fully cooperating or be of potential harm during 
the course of the study.
vii. Abstinent from cocaine for more than two weeks prior to admission.
viii. Hypotensive individuals with sitting blood pressure below 90/50 mmHG.
8. How will eligibility be determined, and by whom? 
Individuals with cocaine use disorder will be interviewed by a research assistant to determine 
interest in participating in this study.  After obtaining written informed consent for 
participation in the study, one of the study physicians will interview the subject and review 
all medical and psychiatric data prior to admitting the subject and beginning medication.
9. Risks: Describe the reasonably foreseeable risks, including risks to subject privacy, 
discomforts, or inconveniences associated with subjects participating in the research. 
i) Pregnenolone/Placebo Treatment:
We selected 300mg/day and 500 mg/day pregnenolone versus placebo dosing based on prior 
clinical trials of pregnenolone in psychiatric patients (men and women). In an 8-week clinical 
trial in schizophrenia patients, fixed escalating dosing from 100mg to 500mg of 
pregnenolone (Marx et al., 2009) was well tolerated. The only side effects present in the 
pregnenolone group to a greater degree than the placebo group were two reports of mild 
restlessness, one report of mild muscle pain/stiffness, and one report of mild cold extremities. 
A follow-up randomized clinical trial in men and women with schizophrenia used escalating 
doses of pregnenolone, 100mg for 2 weeks, 300mg for 2 weeks, 500mg for 4 weeks, and 
found pregnenolone to be safe and well tolerated (Marx et al., 2014). A 12-week randomized 
placebo-controlled trial of escalating doses of pregnenolone to 400mg daily for 4 weeks in 
men and women with bipolar depression improved depressive symptoms and showed 
pregnenolone to be safe and well tolerated in all patients (Brown et al., 2014). A recent study 
using an acute dose of pregnenolone of 400mg to examine the effects of ALLO its effects on 
emotion regulation neurocircuitry (Sripada et al., 2013), also didn’t find any side effects.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 28 of 55
Pregnenolone will be packaged by Connecticut Mental Health Center (CMHC) or the Yale 
Investigational Drug Services (IDS) pharmacist during the inpatient phase, and the Yale 
Investigational Drug Services (IDS) pharmacist during the outpatient phase into labelled 
weekly packs and prepared for randomization, fully matching pregnenolone and placebo 
pills. The CMHC and IDS pharmacies follow stringent procedures to ensure product quality 
and will provide certificates of analysis for purity. Moreover, daily smartphone monitoring 
and thrice-weekly face-to-face appointments will monitor medication safety and tolerability, 
and any adverse events will immediately be reported to a Data Safety monitor and the Yale 
IRB.
ii) Drawing of Blood:
During each laboratory session, about 120mL of whole blood will be drawn to measure stress 
hormone levels that may change during the session, totally 360 mL for all three laboratory 
sessions. The amount of blood drawn over three laboratory sessions is equal to a little over one-
half the blood obtained during a regular blood donation. In order to assess the 
pharmacodymanic/pharmacokinetic profile of pregnenolone administration, 15mL of whole 
blood will be collected at 6 additional timepoints within 24 hours after the second laboratory 
session, totaling an additional 90 mL. In addition, 32 mL of whole blood will be drawn on the 
first day of laboratory session to look at genetic markers, and 10mL of whole blood will be 
drawn during the physical exam/admission procedure to assess eligibility and look at molecular 
adaptations during the study. Lastly, 15 mL of whole blood will also be drawn each at weeks 2, 
5 and 7  to measure pregnenolone levels. These levels will allow staff to ensure subjects are 
taking medication as prescribed. Thus, a total amount of 537 mL of whole blood will be drawn 
throughout the entire study as indicated in the table below. The total amount of blood to be 
drawn is within HHS guidelines of 550 ml within 8 research weeks. People who are in good 
health are not usually affected by this kind of blood loss. However, to be safe, subjects will be 
warned against donating blood for at least eight weeks after completing this study. 
Intake (Week -3)
10mL
Laboratory Sessions (3 Separate Days in 
Week 2)
360mL
24h Cycle (15mlx6) (Lab Day 2)
90mL
Genetic Bloods (Lab Day 1)
32mL
Week 2
15mL
Week 5 
15mL
Week 7
15mL
Total Maximum Amount Drawn 
537mL
iii) Laboratory Sessions:
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 29 of 55
(1). Intravenous (IV) Catheter: When an IV is started, there is some risk that subjects may 
develop a bruise or bleeding where the vein is punctured. If this occurs, appropriate treatment 
will be instituted immediately. On extremely rare occasions, fainting, blood clot or infection 
may occur.
(2). The Imagery Procedures: The imagery method involves reliving a personal stressful 
event and can be somewhat anxiety provoking at the time of the task. Our previous experience 
has shown that once the task is over, there is very little anxiety that carries over, thus posing 
minimal risk. The drug cue imagery involves reliving a personal experience involving drug-
related stimuli associated with drug use. While subjects may feel aroused by the drug cue 
imagery, relaxation procedures have been shown to be successful in reducing the physiological 
arousal associated with cue exposure and stressful imagery.  It is likely that moderate craving 
for drug may occur due to subjects' imagining and reliving stressful events and drug cue related 
events. It is also possible that craving for drug may linger even after the task. 
iv) Breath, saliva, and urine collections
Breath screening, saliva collection, and urine collections are performed primarily as 
safeguards to contamination of data and should add no risks other than those normally 
associated with these procedures. 
v) Rating Scales and Questionnaires
These are all noninvasive and should add no risk. The major disadvantages are the time 
taken to complete them, and possible breach of confidentiality. Our past experience with these 
measures indicates that they are acceptable to subjects. Careful efforts aimed at maintaining 
confidentiality have been effective in previous research, and only patients’ code numbers will be 
recorded on the forms themselves to protect confidentiality.
vi) Nonspecific Risks. Other risks from the counseling, rating scales and urine collections are 
not beyond usual clinical procedures in a substance abuse treatment program.  
Confidentiality of these results are specifically protected by Federal laws, as a certificate of 
confidentiality will be sought for the study;  all records will be identified by code number 
only, with the master file kept under lock by the Principal Investigator or Data Manager.
vii. Risk of breach of confidentiality: It is possible that someone unauthorized may gain 
access and see participants’ private information. Every effort will be made to keep data safe 
and private. For more information about how data will be protected, see below in the 
“Confidentiality & Security of Data “ paragraph.
10. Minimizing Risks: Describe the manner in which the above-mentioned risks will be 
minimized.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 30 of 55
i. Pregnenolone treatment:  
Inclusion criteria and the use of trained research assistants in the initial screening will help to 
avoid the acceptance of subjects that are inappropriate for the study.  Moreover, subjects will 
participate in a comprehensive physical examination conducted at the Yale Stress Center, to rule 
out subjects who may be medically or psychiatrically unfit. These will incorporate stringent 
medical assessments that include electrocardiography and laboratory tests of renal, hepatic, 
pancreatic, haematopoietic and thyroid function. There are no known serious adverse effects of 
pregnenolone. The following precautions will be taken: 1. Vital signs (heart rate, blood pressure, 
body temperature) will be assessed 3 times weekly during the during the face-to-face study 
visits. 2. Any clinically significant physiological signs or other adverse symptoms will be 
monitored closely at each visit to the clinic.
ii. Laboratory Procedures:
The laboratory sessions will be conducted at the Yale Stress Center. For subjects who have 
difficulty reducing their craving levels, relaxation procedures will be conducted to return 
craving levels to baseline after the imagery sessions. We have found that relaxation procedures 
are particularly effective in reducing craving levels after drug cue exposure (Margolin et al., 
1994; Sinha et al., 1999a).  
To enhance their response to relaxation procedures, subjects will also be trained on 
relaxation procedures in a session prior to the laboratory sessions. 
Any subject that reports residual drug craving or emotional discomfort after completion of 
laboratory sessions will receive an individual counseling session by a licensed psychologist who 
is experienced in relapse prevention therapy. The focus of this session will be coping with high-
risk situations and cravings. 
11. Data and Safety Monitoring Plan: Include an appropriate Data and Safety Monitoring Plan 
(DSMP) based on the investigator’s risk assessment stated below. (Note: the HIC will make 
the final determination of the risk to subjects.) For more information, see the Instructions, 
page 24.
a. 
What is the investigator’s assessment of the overall risk level for subjects 
participating in this study? 
b.
If children are involved, what is the investigator’s assessment of the overall risk 
level for the children participating in this study? 
c.
Include an appropriate Data and Safety Monitoring Plan. Examples of DSMPs are  
 available here http://www.yale.edu/hrpp/forms-templates/biomedical.html  for
i. Minimal risk
ii. Greater than minimal
d. For multi-site studies for which the Yale PI serves as the lead investigator:
i. How will adverse events and unanticipated problems involving risks to subjects or 
others be reported, reviewed and managed?
ii. What provisions are in place for management of interim results?
iii. What will the multi-site process be for protocol modifications?
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 31 of 55
This protocol has been deemed a moderate risk protocol.
As this is a pilot efficacy study it does not require a data safety monitoring board. However, 
as drug abusing patients who are considered to be a high-risk and vulnerable population are 
subjects in this study, the following data safety monitoring plan has been put in place.
a.
Data Safety Monitor: The data safety monitor for this study will be Robert D. Beech, 
MD, Ph.D.Phone (203) 974-7757, Email: robert.beech@yale.edu.  Dr. Beech is an Assistant 
Professor at the Department of Psychiatry at Yale University and Medical Director, 
Acute Inpatient Unit and Transitional Living Program at the Connecticut Mental 
Health Center. He has served as PI on several studies and is very familiar with the NIH 
requirements for data safety monitoring. He is not an investigator on this study and will 
function as an independent monitor. 
Dr. Beech will evaluate all Adverse and Serious Adverse Events, and will assist the PI in 
preparing and sending the pertinent expedited reports to the appropriate persons as outlined 
below. He will monitor the study quarterly and review all adverse event sheets completed 
during that period. He will assist the PI in making critical decisions regarding a particular 
subject continuing in a study for safety reasons. He will review the summary of all Adverse 
Events for this study, which will be reported annually to the Yale Human Investigation 
Committee (HIC) and study sponsors.
 
b. Monitoring and Reporting of All Adverse and Serious Adverse Events (AEs and SAEs):  
Data on all unanticipated, serious-related Adverse Events occurring during the course of 
conducting this study will be collected, documented and reported to the Yale HIC. A 
summary of all AE’s will be prepared annually, by the project PI and the Data Safety 
Monitor and submitted to the Yale HIC. The Yale HIC requires the re-approval of study 
protocols at least annually and will not re-approve the protocol without such reports. 
Adverse Events (AE) will be defined on the basis of the NIDA Guidelines on Data and 
Safety Monitoring for Intervention Trials. These guidelines define an AE as any reaction, 
side effect or untoward event that occurs during the course of the clinical trial, whether or not 
the event is considered related to the study interventions.  A new illness, symptom, 
unfavorable or unintended sign, or worsening of a pre-existing condition or abnormality will 
be considered an AE. Stable chronic conditions such as diabetes that are present prior to 
study entry and do not worsen will not be considered AEs.  For all NIDA-MDC studies 
including this one, AEs will include events and symptoms reported by the subjects that are of 
clinical importance as noted by the study staff.  
The following Yale HIC/FDA classification of AE “severity” and “attribution” will be used 
and reported on the Yale/HIC Adverse Reporting Form. 
1. Mild adverse event
2. Moderate adverse event
3. Severe 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 32 of 55
a.) Definite: Adverse event is clearly related to investigational procedures(s)/agent(s).
b.) Probable: Adverse event is likely related to investigational procedures(s)/agent(s).
c.) Possible: Adverse event may be related to investigational procedures(s)/agent(s).
d.) Unlikely: Adverse event is likely not to be related to the investigational 
procedures(s)/agent(s).
e.) Unrelated: Adverse event is clearly not related to investigational procedures(s)/agent(s).
c.
Plan for Determining Seriousness of Adverse Events:
An adverse event may be graded as severe but still not meet the criteria for a Serious Adverse 
Event.  Similarly, an adverse event may be graded as moderate but still meet the criteria for an 
SAE.  It is important for the PI to consider the grade of the event as well as its “seriousness” 
when determining whether reporting to the IRB is necessary.
Each AE will be classified by the project PI as serious or non-serious and appropriate 
reporting procedures will be followed. Serious Adverse Events (SAEs) will be defined on the 
basis of the NIDA Guidelines on Data and Safety Monitoring for Intervention Trials. An 
SAE will be any fatal event, any immediately life-threatening event, any permanent or 
substantially disabling event, any event that requires or prolongs inpatient hospitalization, or 
any congenital anomaly. Any Unexpected Event that suggests a significant hazard, contra-
indication, side effect or precaution will also be reported.
An adverse event may be graded as severe but still not meet the criteria for a Serious Adverse 
Event.  Similarly, an adverse event may be graded as moderate but still meet the criteria for 
an SAE.  It is important for the PI to consider the grade of the event as well as its 
“seriousness” when determining whether prompt reporting to the IRB is necessary.
d. Reporting UPIRSOs (including Adverse Events) to the IRB: The principal investigator 
will report the following types of events to the IRB: 
Any incident, experience or outcome that meets ALL 3 of the following criteria:
1. Is unexpected (in terms of nature, specificity, severity, or frequency) given (a) the 
research procedures described in the protocol-related documents, such as the IRB-approved 
protocol and informed consent document and (b) the characteristics of the subject population 
being studied; AND 
2. Is related or possibly related to participation in the research (possibly related means there 
is a reasonable possibility that the incident, experience, or outcome may have been caused by 
the procedures involved in the research); AND
3. Suggests that the research places subjects or others at greater risk of harm (including 
physical, psychological, economic, legal, or social harm) than was previously known or 
recognized.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs) may be medical or 
non-medical in nature, and include – but are not limited to – serious, unexpected, and related 
adverse events and unanticipated adverse device effects.  Please note that adverse events are 
reportable to the IRB as UPIRSOs only if they meet all 3 criteria listed above.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 33 of 55
These UPIRSOs/SAEs will be reported to the IRB in accordance with IRB Policy 710, using 
the appropriate forms found on the website. All related events involving risk but not meeting 
the prompt reporting requirements described in IRB Policy 710 should be reported to the IRB 
in summary form at the time of continuing review. If appropriate, such summary may be a 
simple brief statement that events have occurred at the expected frequency and level of 
severity as previously documented.  In lieu of a summary of external events, a current DSMB 
report can be submitted for research studies that are subject to oversight by a DSMB (or other 
monitoring entity that is monitoring the study on behalf of an industry sponsor).
e.
Timeframe for Reporting:
1. Events that may require a temporary or permanent interruption of study activities by the 
Principal Investigator or sponsor to avoid potential harm to subjects should be reported to the 
IRB immediately (if possible), followed by a written report to the IRB no more than 5 
calendar days after the Yale Principal Investigator becomes aware of the event.
2. Internal Events (defined above) should be reported to the IRB within 5 calendar days of 
the Principal Investigator becoming aware of the event.
f.
Reporting of Other Study-Safety Events:  The project PI will inform the Data Safety 
Monitor, the Yale HIC, NIDA project officer and the sponsor promptly of any change in 
recruitment or other changes in this project that are relevant to safety, as well as any action 
taken by the Yale HIC as a result of continuing review of this project. 
12. Statistical Considerations: Describe the statistical analyses that support the study design. 
For the pilot study data we will mostly use descriptive statistics for comparing the medication 
groups on primary outcome measures and safety measures.  Repeated measures ANOVA and 
mixed model procedures to assess treatment group differences in cocaine craving and stress 
related arousal (heart rate, blood pressure, HPA and catecholamine responses) during 
laboratory exposure to stress and drug cues as compared to neutral imagery conditions. Non-
parametric tests will be used to assess occurrence of side effects, cocaine use measures, 
CSSA scores and perceived stress scores during the outpatient study phase. The number and 
type of AE’s for the two medication groups will be conducted using t-tests, chi-square tests 
and ANOVAs as appropriate. Findings will be used to estimate effect sizes for the 
medication and guide the larger randomized clinical trial in the future.  
Primary Outcome Measures during 8 week treatment: The primary outcome measures will 
be: (1) protracted withdrawal symptoms, as measured by the CSSA/CIWA and subjective 
cocaine withdrawal scale, (2) cocaine  use as measured by weekly urine drug screens and 
self-report of drug use on the Substance Use Calendar, (3) side effects and adverse events as 
measured by the SAFTEE, and (4) treatment adherence as measured by frequency of 
attendance for medication self-administration and attendance for counseling appointments, 
including missed sessions.
Secondary Outcome Measures:  Secondary outcome measures will include cocaine craving 
scales, perceived stress scale, the recent stressful life events scale (LES), POMS, and the 
COPE Questionnaire. In addition, other assessments will be used to ensure that medications 
groups are not different in various measures at baseline and also to assess their role in 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 34 of 55
predicting treatment response. Examples of such assessments would be demographic 
measures, depressive and anxiety symptoms, motivation to change and thoughts about 
abstinence, which are measures that have been found to predict substance abuse treatment 
outcomes (Hall et al., 1990; 1991; McMahon et al., 1986).  
Data Analytic Procedures: Since patients will be randomly assigned to the pregnenolone 
doses and placebo treatment groups, we do not expect the groups to be different on 
demographic, prior drug use history or other predictor variables.  Nevertheless, prior to 
undertaking the specific analyses, we will compare the treatment groups on demographic 
variables, substance use characteristics and previous psychiatric history/predictor variables 
using t-tests/chi-square analyses as appropriate. If any group differences are found, the 
specific variable will be entered as a covariate in all of the specific analyses.
The laboratory study proposes a 3 X 2 X 3 mixed-factorial design with Treatment (300mg 
Pregnenolone vs. 500mg Pregnenolone vs. Placebo) and Sex (CUD women vs. men) as the 
Between-Subjects factors and Imagery Condition (Stress, Drug Cues and Neutral cues) X 
Time Period 7 (Baseline, Image, Recovery 1, recovery 2, recovery3, Recovery 4 and 
Recovery 5) as the Within-Subjects factors. Order of imagery conditions will be randomly 
assigned and counterbalanced across subjects. As measurements for imagery condition and 
time period will be repeated within subjects, these are not independent, leading to 
correlations between measurements. Mixed linear models provide a way not only to model 
the mean differences between levels of factors, but also allows for modeling of the variance-
covariance matrices (Laird and Ware 1982) (Littell, Milliken et al. 1996). This is particularly 
advantageous for designs such as the one proposed here which require repeated laboratory 
measurements within subjects. Furthermore, these models also have the capacity to handle 
missing data, without excluding subjects with missing data points (Cnaan et al., 1997; Littell 
et al., 1996).
Thus, mixed linear models will be used to test the hypotheses for each of the specific aims. In 
each case, Subjects will be treated as a random effect and Sex, Imagery Condition and Time-
period will be treated as fixed effects. PROC MIXED in the Statistical Analysis System 
(SAS, version 9.3) will be used to model the experimental effects. Each of the specific aims 
and hypotheses are listed below. For the outpatient section of the study, Cox Proportional 
Hazards models will be used to ascertain differences in time to relapse between CUD 
individuals treated with pregnenolone compared with those treated with placebo. We 
anticipate that pregnenolone-treated individuals will demonstrate a survival function 
reflecting an increase in number of days to relapse compared to the placebo group.
Aim 1: To examine the effects of PREG doses vs PLA on experimentally provoked cue- and 
stress induced craving, anxiety, emotion, cognitive flexibility and on ACTH, cortisol and 
cardiovascular arousal as compared to neutral imagery in CUD men and women: Linear Mixed 
Effect (LME) models will be used to analyze data, using SPSS. Within subject factors of Imagery 
Condition (stress, cocaine cue, neutral), Time-point (varying levels) and the Between-subjects factors 
of Medication Group (two doses of PREG/PLA) and Gender (males/females) will be the fixed 
effects. Subjects will represent the random effect. T-tests and Chi-square analyses will be used to 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 35 of 55
examine group differences in demographic variables. The Bonferroni test for multiple comparisons 
will be used to analyze simple effects. We anticipate significant Medication X Imagery Condition, or 
Medication X Imagery Condition X Timepoint interactions. 
Aim 2: To examine the safety and PK/PD profile of two doses of PREG (300mg; 500mg; bid), 
and matching placebo (PLA) over a 24 hour period in CUD men and women: Repeated 
measures ANOVA and LME models will be used to compare PREG vs PLA in terms of adverse 
events and kinetic properties. Significance will be set at P-value ≤ 0.05 and data will be processed by 
SPSS. Any serious adverse events will be considered as significant and will be subject to further 
analysis. Based on preliminary data, we hypothesize that PREG will be well tolerated and will dose-
dependently reduce cocaine craving and improve mood compared to the PLA group. We anticipate 
that ALLO will mediate these effects. All analyses will be conducted using the LME procedure using 
SPSS, which accounts for the interdependence associated with multiple repeated measures within the 
same individual. 
Exploratory Aim 1: To explore the preliminary efficacy of 8-week PREG (300 and 500 mg/day) 
vs PLA on primary outcomes of cocaine craving and negative mood symptoms, and secondary 
cocaine use outcomes: Cocaine use measures will be based primarily on objective 2X/week urine 
results, and self-reported cocaine use (from SUC and daily EMA) yielding weekly cocaine use 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 36 of 55
frequency, amount and continuous abstinence weeks. Urine drug screen will serve as the gold 
standard and missing data points will be treated as positive. 
Exploratory Aim 2: To explore sex/gender differences in each of the above aims: Gender will be 
included as a factor in all LME models above to investigate gender main effects and interactions in 
the above aims. 
SECTION VI: RESEARCH INVOLVING DRUGS, BIOLOGICS, RADIOTRACERS, PLACEBOS AND 
DEVICES
If this section (or one of its parts, A or B) is not applicable, state N/A and delete the rest of the 
section.
A.  DRUGS, BIOLOGICS and RADIOTRACERS
1. Identification of Drug, Biologic or Radiotracer: What is (are) the name(s) of the drug(s) 
biologic(s)  or radiotracer(s) being used? Identify whether FDA approval has been granted and for 
what indication(s). 
Pregnenolone is a naturally occurring steroid, which is available as a dietary supplement in health 
stores. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), a dietary 
supplement is not considered a drug if the intended use is only to affect any function of the body. In 
this pilot study, we are looking at pregnenolone’s effect on function in the body and we will be 
collecting preliminary drug use outcome data. 
All protocols which utilize a drug, biologic or radiotracer not approved by, but regulated by, the FDA, 
or a radiotracer regulated by the RDRC, must provide the following information:  
a. What is the Investigational New Drug (IND) number assigned by the FDA?
b. Who holds the IND? 
c. All protocols which utilize a radiotracer not approved by, but regulated by the FDA must 
provide the IND number: _______________
Alternatively, use of the investigational radiotracer may be under RDRC/RSC oversight: (check 
if appropriate)_____________
For all investigational radiotracers, attach a copy of the RDRC/RSC application (for 
radioisotopes used in the PET Center, PET Center personnel may complete this step)
Go to http://rsc.med.yale.edu/login.asp?url=myApps.asp.  When you have logged in, complete 
the application and attach a copy to this submission.     
Alternatively, an exemption from IND filing requirements may be sought for a clinical
 investigation of a drug product that is lawfully marketed in the United States. If there is no IND and
 an exemption is being sought, review the following categories and complete the category that applies
 (and delete the inapplicable categories):
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 37 of 55
Exempt Category 1
The clinical investigation of a drug product that is lawfully marketed in the United States can be
exempt from IND regulations if all of the following are yes:
i.   The intention of the investigation is NOT to report to the FDA as a well-controlled study in support
     of a new indication for use or to be used to support any other significant change in the labeling for
     the drug.  
 Yes  
 No
ii. The drug that is undergoing investigation is lawfully marketed as a prescription drug product, and
      the intention of the investigation is NOT to support a significant change in the advertising for the
      product. 
 Yes  
 No
iii.  The investigation does NOT involve a route of administration or dosage level or use in populations
      or other factor that significantly increases the risks (or decreases the acceptability of the risks)   
      associated with the use of the drug product. 
 Yes  
 No
iv. The investigation will be conducted in compliance with the requirements for institutional (HIC)   
      review and with the requirements for informed consent of the FDA regulations (21 CFR Part 50  
and 21 CFR Part 56). 
 Yes  
 No
v.   The investigation will be conducted in compliance with the requirements regarding promotion and 
charging for investigational drugs. 
 Yes  
 No
Exempt Category 2 (all items i, ii, and iii must be checked to grant a category 2 exemption)
 i. The clinical investigation is for an in vitro diagnostic biological product that involves one or
more of the following (check all that apply):
 Blood grouping serum
 Reagent red blood cells 
 Anti-human globulin
 ii. The diagnostic test is intended to be used in a diagnostic procedure that confirms the
diagnosis made by another, medically established, diagnostic product or procedure; and
 iii. The diagnostic test is shipped in compliance with 21 CFR §312.160.
Exempt Category 3
 The drug is intended solely for tests in vitro or in laboratory research animals if shipped in 
accordance with 21 CFR 312.60
Exempt Category 4
 A clinical investigation involving use of a placebo if the investigation does not otherwise 
require submission of an IND.
2. Background Information: Provide a description of previous human use, known risks, and data 
addressing dosage(s), interval(s), route(s) of administration, and any other factors that might 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 38 of 55
influence risks. If this is the first time this drug is being administered to humans, include relevant 
data on animal models. 
Recent studies using the neuroactive steroid precursor PREG, found that it improved negative and 
cognitive symptoms, and functional capacity in men and women with schizophrenia, as compared 
to placebo (Marx et al., 2009; Marx et al., 2014)) and that PREG-induced increases in ALLO 
levels were associated with enhanced activation of the emotion regulation neurocircuitry in healthy 
controls (Sripada et al., 2013). A randomized placebo-controlled trial of PREG in men and women 
with bipolar depression improved depressive symptoms and showed PREG to be safe and well 
tolerated in all patients (Brown et al., 2014). Importantly, in all these studies PREG markedly 
increased ALLO levels, which significantly correlated with the outcome measures, representing a 
robust “precursor loading” strategy for ALLO enhancement (Marx et al., 2014). Although PREG 
use in psychiatric conditions is only emerging, preclinical evidence shows promise with recent 
reports of PREG reducing alcohol self-administration in alcohol-preferring rats (Besheer et al., 
2010) and also reducing cannabis intoxication effects in mice and rats (Vallee et al., 2014). There 
is increasing interest in pregnenolone in psychiatric disorders, and current studies of pregnenolone 
on clinicaltrials.gov reveal that pregnenolone has been and/or is currently tested in a range of 
psychiatric disorders such as in veterans with mild TBI, in the treatment of schizophrenia, 
withdrawal symptoms and craving in male cigarette smokers, PTSD, bipolar depression and 
marijuana dependence, among others.
We selected 300 mg/day and 500 mg/day versus placebo dosing based on prior clinical trials of 
pregnenolone in psychiatric patients (men and women). In an 8-week clinical trial in schizophrenia 
patients, fixed escalating dosing from 100mg to 500mg of pregnenolone (Marx et al., 2009) was 
well tolerated. The only side effects present in the pregnenolone group to a greater degree than the 
placebo group were two reports of mild restlessness, one report of mild muscle pain/stiffness, and 
one report of mild cold extremities. A follow-up randomized clinical trial in men and women with 
schizophrenia used escalating doses of pregnenolone, 100mg for 2 weeks, 300mg for 2 weeks, 
500mg for 4 weeks, and found pregnenolone to be safe and well tolerated (Marx et al., 2014). A 
12-week randomized placebo-controlled trial of escalating doses of pregnenolone to 400mg daily 
for 4 weeks in men and women with bipolar depression improved depressive symptoms and 
showed pregnenolone to be safe and well tolerated in all patients (Brown et al., 2014). A recent 
study using an acute dose of pregnenolone of 400mg to examine the effects of ALLO its effects on 
emotion regulation neurocircuitry (Sripada et al., 2013), also didn’t find any side effects.
3. Source: a) Identify the source of the drug or biologic to be used. 
Medication Administration and Compliance: Pregnenolone pills will be purchased through 
the  Yale Investigational Drug Services (IDS) pharmacy and the research pharmacist will 
make up identical active and placebo capsules, packaged into weekly packs for medication 
self-administration. Subjects will be randomly assigned to twice daily dosing of 300mg and 
500mg PREG/PLA. Subjects will self-administer study medication twice daily. Study staff 
will monitor vital signs and side effects during bi-weekly face-to-face appointments. We 
expect all subjects to tolerate  doses of 300mg and 500mg pregnenolone.  Cocaine craving, 
abstinence symptoms, mood and perceived stress scale and side effects will be assessed twice 
weekly. Urines will be obtained twice weekly. 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 39 of 55
Medication compliance will be monitored by blood draws done at weeks 2, 5, and 7, to measure 
PREG levels, and through the monitoring of riboflavin as a urine marker. Riboflavin produces a 
bright yellow discoloration of the urine when the medication is taken 2 to 8 hours prior. Subjects 
will be taking morning and bedtimes doses of the medication. After this time, staff will easily be 
able to visually inspect the subject’s urine to determine whether the morning dose has been 
taken. 25mg of riboflavin will be added to all doses of PREG and PLA by the pharmacist when 
capsules are made.  
Subjects will self-administer study medication, and will be reminded via daily smartphone 
platform monitoring. Daily smartphone monitoring will be used to prompt patients to take 
study medication, and also to assess cocaine use, craving, craving resistance and mood states. 
Concordance between daily smartphone reports and cocaine positive urines will be evaluated 
for daily versus retrospective reporting.
Medication compliance will also be implemented/monitored through video Directly 
Observed Therapy (DOT) using the smartphone application eMocha. Subjects will use the 
eMocha app to video record themselves taking their medication. Research staff will log into a 
secure site to view the recorded videos to assess medication dose adherence.
All participants and study staff will remain blind to medication condition. 
b) Is the drug provided free of charge to subjects? 
 Yes  
 No
    If yes, by whom? 
4. Storage, Preparation and Use: Describe the method of storage, preparation, stability information, 
and for parenteral products, method of sterilization and method of testing sterility and 
pyrogenicity. 
Commercially available pregnenolone tablets will be used. 
Check applicable Investigational Drug Service utilized:
     
   YNHH IDS                                                                      
   Yale Cancer Center 
     
   CMHC Pharmacy                                                          
  West Haven VA
     
   PET Center                                                     
    None      
     
    Other: 
Note: If the YNHH IDS (or comparable service at CMHC or WHVA) will not be utilized, explain in 
detail how the PI will oversee these aspects of drug accountability, storage, and preparation.  
  
5. Use of Placebo: 
 Not applicable to this research project
If use of a placebo is planned, provide a justification which addresses the following:
1.
Describe the safety and efficacy of other available therapies. If there are no other
available therapies, state this.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 40 of 55
b.   State the maximum total length of time a participant may receive placebo while on the study. 
c.   Address the greatest potential harm that may come to a participant as a result of  receiving    
  
   placebo. 
d.   Describe the procedures that are in place to safeguard participants receiving placebo. 
There are currently no approved medication therapies for cocaine use disorders. Subjects will 
receive placebo for no more than 5 weeks. All subjects will receive psychosocial treatment that is 
currently equivalent to any pharmacological treatment available. All participants will receive 
weekly drug counseling with an addiction expert.
6. Use of Controlled Substances:
Will this research project involve the use of controlled substances in human subjects?
 Yes  
 No See HIC Application Instructions to view controlled substance listings. 
7. Continuation of Drug Therapy After Study Closure   
 Not applicable to this project
Are subjects provided the opportunity to continue to receive the study drug(s) after the study has 
ended?
 
 Yes   If yes, describe the conditions under which continued access to study drug(s) may apply 
as well as conditions for termination of such access. 
 
 No    If no, explain why this is acceptable.
 B.  DEVICES- NA
      SECTION VII: RECRUITMENT/CONSENT AND ASSENT PROCEDURES 
1. Targeted Enrollment: Give the number of subjects: 60 
a.
  targeted for enrollment at Yale for this protocol_60__
b.    If this is a multi-site study, give the total number of subjects targeted across all 
sites___ 
2. Indicate recruitment methods below.  Attach copies of any recruitment materials that will be used.
 Flyers
 Internet/Web Postings
 Radio
 Posters
 Mass E-mail Solicitation
 Telephone
 Letter
 
 Departmental/Center Website
 Television
 Medical Record Review
 Departmental/Center Research Boards
 Newspaper
 Departmental/Center Newsletters
 Web-Based Clinical Trial Registries
  YCCI Recruitment database
 Clinicaltrials.gov Registry (do not send materials to HIC)
 Other (describe):
3.  Recruitment Procedures: 
a.
Describe how potential subjects will be identified.
b.
Describe how potential subjects are contacted. 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 41 of 55
c.
Who is recruiting potential subjects? 
Subjects will be recruited through flyers and advertisements in local newspapers, internet/web 
postings, through YCCI’s recruitment database Yale’s clinical research management system (CRMS)- 
OnCore, and from community substance abuse treatment facilities. Subjects will participate in an 
initial phone screening and intake session to obtain informed consent with the research coordinator or 
research assistant, followed by physical examination and blood work to determine eligibility.
4. Screening Procedures
a.
Will email or telephone correspondence be used to screen potential subjects for 
eligibility prior to the potential subject coming to the research office? 
 Yes  
 No
b.
 If yes, identify below all health information to be collected as part of screening and 
check off any of the following HIPAA identifiers to be collected and retained by the 
research team during this screening process. 
HEALTH INFORMATION TO BE COLLECTED:
Subjects will be asked if they have any current or past medical, e.g. neurological, cardiac, endocrine, 
cancer etc.,  or psychiatric conditions, e.g. depression, suicidal attempts. They will be asked if they 
received any past medications for psychiatric conditions. Also, they will be asked if they are currently 
on any medications, and if so, to list them. Subjects will also be asked about past and current 
drug/alcohol use. 
 
HIPAA identifiers: 
 Names 
 All geographic subdivisions smaller than a State, including: street address, city, county, precinct, zip codes and their 
equivalent geocodes, except for the initial three digits of a zip code if, according to the current publicly-available data from 
the Bureau of the Census: (1) the geographic unit formed by combining all zip codes with the same three initial digits contains 
more than 20,000 people, and (2) the initial three digits of a zip code for all such geographic units containing 20,000 or fewer 
people is changed to 000. 
  Telephone numbers
 Fax numbers 
 E-mail addresses
 Social Security numbers 
 Medical record numbers
 Health plan beneficiary numbers 
 Account numbers 
  All elements of dates (except year) for dates related to an individual, including: birth date, admission date, discharge 
date, date of death, all ages over 89 and all elements of dates (including year) indicative of such age, except that such ages 
and elements may be aggregated into a single category of age 90 or older 
 Certificate/license numbers 
 Vehicle identifiers and serial numbers, including license plate numbers 
 Device identifiers and serial numbers 
 Web Universal Resource Locators (URLs) 
 Internet Protocol (IP) address numbers 
 Biometric identifiers, including finger and voice prints 
 Full face photographic images and any comparable images 
 Any other unique identifying numbers, characteristics, or codes 
5. Assessment of Current Health Provider Relationship for HIPAA Consideration:
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 42 of 55
Does the Investigator or any member of the research team have a direct existing clinical 
relationship with any potential subject? 
 Yes, all subjects
 Yes, some of the subjects
 No
If yes, describe the nature of this relationship.
6. Request for waiver of HIPAA authorization: (When requesting a waiver of HIPAA Authorization 
for either the entire study, or for recruitment purposes only.  Note: if you are collecting PHI as part of 
a phone or email screen, you must request a HIPAA waiver for recruitment purposes.)
Choose one: 
☐ For entire study 
☒ For recruitment purposes only
☐ For inclusion of non-English speaking subject if short form is being used
i. Describe why it would be impracticable to obtain the subject’s authorization for 
use/disclosure of this data;
ii. If requesting a waiver of signed authorization, describe why it would be 
impracticable to obtain the subject’s signed authorization for use/disclosure of this 
data;
The recruitment will begin with a screening questionnaire over the phone, for which 
subjects will be asked to give a verbal consent, but a signature cannot be obtained. Once 
potential subjects have completed the phone screening and appear to be eligible, they will 
be invited for an intake appointment, during which a signed authorization and consent 
will be obtained. 
By signing this protocol application, the investigator assures that the protected 
health information for which a Waiver of Authorization has been requested will not 
be reused or disclosed to any person or entity other than those listed in this 
application, except as required by law, for authorized oversight of this research 
study, or as specifically approved for use in another study by an IRB.
Researchers are reminded that unauthorized disclosures of PHI to individuals outside of the Yale 
HIPAA-Covered entity must be accounted for in the “accounting for disclosures log”, by subject 
name, purpose, date, recipients, and a description of information provided.  Logs are to be 
forwarded to the Deputy HIPAA Privacy Officer.
7. Required HIPAA Authorization: If the research involves the creation, use or disclosure of 
protected health information (PHI), separate subject authorization is required under the 
HIPAA Privacy Rule. Indicate which of the following forms are being provided:
 Compound Consent and Authorization form
 HIPAA Research Authorization Form
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 43 of 55
8. Consent Personnel: List the names of all members of the research team who will be obtaining 
consent/assent. 
See IRES IRB Study Team.
9. Process of Consent/Assent: Describe the setting and conditions under which consent/assent will 
be obtained, including parental permission or surrogate permission and the steps taken to ensure 
subjects’ independent decision-making. 
Potential study participants will be interviewed by a research assistant to determine interest in 
participating in this research study.  After obtaining written informed consent for participation in 
the study, one of the study physicians will interview the subject and review all medical and 
psychiatric data prior to admitting the subject and beginning medication.
10. Evaluation of Subject(s) Capacity to Provide Informed Consent/Assent: Indicate how the 
personnel obtaining consent will assess the potential subject’s ability and capacity to consent to the 
research being proposed. 
The Investigator will not enroll subjects in the study who are determined to have limited 
decision-making capacity.  Prior to consent procedures, breathalyzers will be conducted.  
Subjects whose breathalyzer registers above the legal limit for alcohol will not be consented for 
the study.  Subjects will be assessed throughout the consent process to ensure their understanding 
of consent procedures.
11. Documentation of Consent/Assent: Specify the documents that will be used during the 
consent/assent process. Copies of all documents should be appended to the protocol, in the same 
format that they will be given to subjects. 
1 Document:
Research study consent
12. Non-English Speaking Subjects: Explain provisions in place to ensure comprehension for 
research involving non-English speaking subjects. If enrollment of these subjects is anticipated, 
translated copies of all consent materials must be submitted for approval prior to use. 
Non-English speaking subjects will not be enrolled into this study
12(a) As a limited alternative to the above requirement, will you use the short form* for 
consenting process if you unexpectedly encounter a non-English speaking individual interested 
in study participation and the translation of the long form is not possible prior to intended 
enrollment? 
YES ☐  NO ☐
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 44 of 55
Note* If more than 2 study participants are enrolled using a short form translated into the same 
language, then the full consent form should be translated into that language for use the next time 
a subject speaking that language is to be enrolled.
Several translated short form templates are found on our website 
at:  http://www.yale.edu/hrpp/forms-templates/biomedical.html. If the translation of the short 
form is not available on our website, then the translated short form needs to be submitted to the 
IRB office for approval via amendment prior to enrolling the subject. Please review the 
guidance and presentation on use of the short form available on the HRPP website.
If using a short form without a translated HIPAA Research Authorization Form, please 
request a HIPAA waiver in the section above. 
13. Consent Waiver: In certain circumstances, the HIC may grant a waiver of signed consent, or 
a full waiver of consent, depending on the study. If you will request either a waiver of consent, 
or a waiver of signed consent for this study, complete the appropriate section below.  
 
 Not Requesting a consent waiver 
 
 Requesting a waiver of signed consent
       
 Requesting a full waiver of consent
   
A. Waiver of signed consent: (Verbal consent from subjects will be obtained. If PHI is 
collected, information in this section must match Section VII, Question 6)
 Requesting a waiver of signed consent for Recruitment/Screening only 
If requesting a waiver of signed consent, please address the following:
a. Would the signed consent form be the only record linking the subject and the research? 
 Yes  
 No
b. Does a breach of confidentiality constitute the principal risk to subjects? 
 Yes  
 No
OR
c. Does the research activity pose greater than minimal risk? 
 Yes If you answered yes, stop. A waiver cannot be granted.  Please note: 
Recruitment/screening is generally a minimal risk research activity  
 No 
AND
d. Does the research include any activities that would require signed consent in a non-
research context? 
 Yes  
 No
SECTION VIII: PROTECTION OF RESEARCH SUBJECTS
    Confidentiality & Security of Data:
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 45 of 55
a.    What protected health information (medical information along with the HIPAA identifiers) 
about subjects will be collected and used for the research?   
Results of the physical examination, psychological assessments, self-reports, and data collected 
during the lab session will be collected and used for research. The proposed study will be 
conducted by specialized and trained research staff using standardized biophysiological and 
psychosocial assessments. Data collected and analyzed in the study will be derived from three 
main sources (1) semi-structured clinical interviews and self-rating scales: psychiatric history, 
medical history, levels of alcohol and cocaine use and demographic self-reports of age, race, 
socioeconomic status, marital status, educational and occupational levels. (2)  Biophysiological 
data: includes heart rate, blood pressure, saliva, pregnenolone levels, and plasma HPA axis 
markers (cortisol and ACTH). Additionally, health checks prior to  enrollment will comprise a 
physical examination and blood work. (3) Urine and breathalyzer data: will be used to confirm 
alcohol and substance use.  It will be collected at intake, 3x weekly during outpatient appointments, 
and at follow-up interviews.  
The screening of subjects using the inclusion and exclusion criteria, and the comprehensive 
medical and psychiatric evaluation will minimize the risk of including subjects who are otherwise 
inappropriate. Confidentiality in regard to collected materials will be maintained via a numbered 
reference system maintained by the Project Coordinator. Subjects’ names will appear only on a 
consent form and “key” form kept by the PI and the Project Coordinator in a separate location.
Subjects will be admitted to the Connecticut Mental Health Center (CMHC) as part of their study 
procedures, and a CMHC medical record will be created for them, unless they already have one. 
The information that will be entered into the medical record will include the following: social 
security number, name, address, phone number, and physical exam results. A Certificate of 
Confidentiality (CoC) offers protection against compelled identification of research participants 
by name or other identifying information in any legal proceeding.
       
b.    How will the research data be collected, recorded and stored? 
c.    How will the digital data be stored? 
 CD  
 DVD  
 Flash Drive  
 Portable Hard   
       Drive  
 Secured Server  
 Laptop Computer  
 Desktop Computer  
 Other
d.    What methods and procedures will be used to safeguard the confidentiality and security of    
the identifiable study data and the storage media indicated above during and after the subject’s 
participation in the study?
Upon enrollment, all study subjects will be assigned a unique study number. The study 
number—and no personal identifiers—will be used as labels for study records, samples and 
any other related research documentation. All electronic and digital files will be stored on the 
secure Yale network, and the PC accessing the network will be password protected and 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 46 of 55
encrypted. All paper files, such as consent forms, will be stored in a locked file cabinet in a 
locked office and access is limited to members of the study research team.
Do all portable devices contain encryption software? 
 Yes   
 No NA as per above
         If no, see http://hipaa.yale.edu/guidance/policy.html
 
e.
What will be done with the data when the research is completed? Are there plans to destroy     
the identifiable data? If yes, describe how, by whom and when identifiers will be destroyed. If 
no, describe how the data and/or identifiers will be secured.
Upon completion of study and data analysis, a professional information protection, storage, 
and disposal company will be retained to dispose of research files and informed consent 
documentation.
f.   Who will have access to the protected health information (such as the research sponsor, the  
investigator, the research staff, all research monitors, FDA, Yale Cancer Center Data and Safety 
Monitoring Committee (DSMC), SSC, etc.)? (please distinguish between PHI and de-identified 
data) 
All de-identified data will be available to the research investigator PI, Co-Investigator, 
statistician, DSM, research staff responsible for entering data, NIAAA, Yale HRRP, and Yale’s 
HIC. Protected Health Information will be available to the research physician, and research staff 
only when deemed necessary.  
g.   If appropriate, has a Certificate of Confidentiality been obtained?
A Certificate of Confidentiality has been obtained from the National Institutes of Health.  The 
Certificate expires on 03/31/2023.
h.   Are any of the study procedures likely to yield information subject to mandatory reporting   
requirements? (e.g. HIV testing – reporting of communicable diseases; parent interview -incidents 
of child abuse, elderly abuse, etc.). Please verify to whom such instances will need to be reported. 
Mandatory reporting of incidents of abuse or neglect of a child or elderly person as required by 
Connecticut State law will be complied with. Additionally, certain reportable infectious diseases 
such as HIV and Hepatitis B and C will be reported to the appropriate state agency, although these 
will not be tested by the study. We may also need to intervene and report information regarding 
threat of injury to self or others to the proper authorities. All of these requirements will be complied 
with.
SECTION IX: POTENTIAL BENEFITS
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 47 of 55
Potential Benefits: Identify any benefits that may be reasonably expected to result from the 
research, either to the subject(s) or to society at large. (Payment of subjects is not considered a 
benefit in this context of the risk benefit assessment.) 
The proposed study has the potential to reveal novel mechanisms that may play a role in cocaine 
addiction. A better understanding of cocaine use disorder is of utmost importance, as we still 
don’t have effective FDA approved medications for cocaine use disorders. Understanding the 
potential role on neuroactive steroids in cocaine addiction could also aid in our knowledge of the 
role of sex hormones and their precursors and derivatives in this disorder, and thereby allow us 
to potentially address gender differences that exist in the development, progression and relapse 
of cocaine use disorder. 
         SECTION X: RESEARCH ALTERNATIVES AND ECONOMIC CONSIDERATIONS
1.     Alternatives: What other alternatives are available to the study subjects outside of the research?
Subjects need not participate in this study to receive treatment for substance dependence, such as 
counseling, group therapy, psychotherapy.
2. 
Payments for Participation (Economic Considerations): Describe any payments that will be 
made to subjects, the amount and schedule of payments, and the conditions for receiving this 
compensation. 
Subjects completing the Study, will receive $20 for the first intake interview session, $30 for the 
second, and $20 for the third intake session. They will receive a $50 bonus for inpatient 
admission/outpatient study enrollment, and $100 for each of the 3 laboratory sessions. Subjects 
will also be paid a $50 bonus for completing the laboratory sessions. Therefore, for the 
completion of all procedures leading up to and including the laboratory sessions, subjects will 
receive a total of $470.
If a subject continues on to complete the treatment phase, they will earn chances to win dollar 
prizes for kept appointments to encourage appointment attendance. For every twice/weekly 
appointments they attend, the chance to draw a prize from the fishbowl will increase by one. The 
fishbowl prizes are in increments of $1, $5, $20, and $100. Subjects will participate in this at 
every twice/weekly appointment they attend. If they miss any appointment, or fail to take study 
medication, the chances will be reset back to one. For example, if no appointments are missed 
the subject will have a total of 8 chances at the last appointment. Each prize increment that is 
won from the 8 attempts is then added together into a lump sum. There is no limit on the 
amounts that can be won. Subjects participating in smartphone monitoring will be compensated 
for their participation at $2 a day, with a $6 bonus for completing all 7 days, hence a possible 
total of $20 a week, for the duration of the outpatient phase. A standard payment rate of $20 per 
week can be used in lieu of drawing from the fish bowl in order to encourage completion of 
appointments.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 48 of 55
In addition, subjects will receive  $20 for week 5, and a $20 bonus for completing the outpatient 
treatment phase. Subjects will receive $25 per week for taking study medication using eMocha for a 
total of $200 for completing all 8 weeks. The total that subjects may be reimbursed if they complete 
all aspects of the study will be $830 (as indicated in a table below) plus the various amounts won for 
keeping appointments during the outpatient phase.
Subjects’ potential costs for parking or transportation may be paid by the study and/or reimbursed.
If a subject decides to not continue with the outpatient phase, twice-weekly follow-up 
appointments for one week will be scheduled after the laboratory sessions are complete. They 
will receive $25 for each visit. Therefore, if subjects only complete the laboratory phase with the 
follow up visits, the total payment will be $520.
Intake (20+30+20) + Bonus (50)
$120
Laboratory Sessions (100x3) + Bonus 
(50)
$350
Fishbowl Lottery
Not included in count
Flat payment in lieu of fishbowl/week 
(20x8)
$160
Smartphone (20/per week= 20x8)
$160
Week 5 Bonus (20)
$20
Week 8 Bonus (20)
$20
Total Payment (not incl. fishbowl)
$830
3.
Costs for Participation (Economic Considerations): Clearly describe the subject’s costs 
associated with participation in the research, and the interventions or procedures of the study that 
will be provided at no cost to subjects.   
  
There will be no costs charged to subjects who participate in this study.  All evaluations 
including interviews, physical exams, diagnostic tests will be provided at no cost to the subjects.
4.
In Case of Injury: This section is required for any research involving more than minimal risk.
a.     Will medical treatment be available if research-related injury occurs? 
b.     Where and from whom may treatment be obtained? 
c.     Are there any limits to the treatment being provided? 
d.     Who will pay for this treatment? 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 49 of 55
e.     How will the medical treatment be accessed by subjects? 
While medical therapy will be offered for any physical injuries sustained as a consequence of 
participation in this research, the subject and their insurance carrier will be responsible for the cost 
of such treatment. Financial compensation for injury is not available.  
REFERENCES
Barbaccia, M.L., Roscetti, G., Bolacchi, F., Concas, A., Mostallino, M.C., Purdy, R.H., Biggio, G., 
1996. Stress-induced increase in brain neuroactive steroids: antagonism by abecarnil. 
Pharmacology, biochemistry, and behavior 54, 205-210.
Beck, A., C. Ward, et al., (1961). “An inventory for measuring depression.” Archives of General 
Psychiatry 4: 461-471.
Besheer, J., Lindsay, T.G., O'Buckley, T.K., Hodge, C.W., Morrow, A.L., 2010. Pregnenolone and 
ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats. Alcohol Clin 
Exp Res 34, 2044-2052.
Biggio, G., Concas, A., Follesa, P., Sanna, E., Serra, M., 2007. Stress, ethanol, and neuroactive 
steroids. Pharmacology & therapeutics 116, 140-171.
Bradley, B. P., Phillips, G., Green, L., Gossop, M., (1989). "Circumstances surrounding the initial 
lapse to opiate use following detoxification." Br. J. Psychiatry. 154, 354-359.
Bohn, M., D. Krahn, et al., (1995). “Development and initial validation of a measure of drinking urges 
in abstinent alcoholics.” Alcoholism, Clinical and Experimental Research 19(3): 600-6.
Brown, E.S., Park, J., Marx, C.E., Hynan, L.S., Gardner, C., Davila, D., Nakamura, A., Sunderajan, P., 
Lo, A., Holmes, T., 2014. A randomized, double-blind, placebo-controlled trial of pregnenolone 
for bipolar depression. Neuropsychopharmacology 39, 2867-2873.
Budney, A.J. & Higgins, S.T. (1998). A community reinforcement plus vouchers approach: Treating 
cocaine addiction, USDHHS, Rockville, MD 
Cacciola, J. S., Alterman, A. I., O'Brien, C. P., McLellan, A. T. 1997. The Addiction Severity Index in 
clinical efficacy trials of medications for cocaine dependence. NIDA Research Monograph 
Series No. 175. Rockville, MD: NIDA. p 182-191.
Carey, K.B. (1997). Challenges in assessing substance use patterns in persons with comorbid mental 
and addictive disorders. NIDA Res Monogr,172:16-32.
Carver, C. S., Scheier, M. F., Weintraub, J. K., (1989). "Assessing coping strategies: A theoretically 
based approach." J. Pers. Soc. Psychol. 56, 267-283.
Cepeda-Benito, A., Tiffany, S. T., 1996. The use of a dual-task procedure for the assessment of 
cognitive effort associated with smoking urges. Psychopharmacology (Berl). 127, 155-163.
Cohen, S., Kamarck, T., Mermelstein, R., 1983. A global measure of perceived stress. J. Health Soc. 
Behav. 24, 385-396.
Cohen, S., Lichtenstein, E., 1990. Perceived stress, quitting smoking, and smoking relapse. Health 
Psychol. 9, 466-478.
Concas, A., Mostallino, M.C., Porcu, P., Follesa, P., Barbaccia, M.L., Trabucchi, M., Purdy, R.H., 
Grisenti, P., Biggio, G., 1998. Role of brain allopregnanolone in the plasticity of gamma-
aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proceedings 
of the National Academy of Sciences of the United States of America 95, 13284-13289.
Cook, E., B. Melamed, et al., (1988). “Emotional imagery and the differential diagnosis of anxiety.” 
Journal of Consulting and Clinical Psychology 56: 734-740.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 50 of 55
Cooney, N. L., Litt, M. D., Morse, P. A., Bauer, L. O., Gaupp, L., (1997). "Alcohol cue reactivity, 
negative mood reactivity, and relapse in treated alcoholic men." JAP. 106, 243-250.
Crowley, S.K., Girdler, S.S., 2014. Neurosteroid, GABAergic and hypothalamic pituitary adrenal 
(HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology 
231, 3619-3634.
Daughters, S. B., J. M. Richards, S. M. Gorka and R. Sinha (2009). "HPA axis response to 
psychological stress and treatment retention in residential substance abuse treatment: a 
prospective study." Drug Alcohol Depend 105(3): 202-208.
Drobes, D. J., Tiffany, S. T., 1997. Induction of smoking urge through imaginal and in vivo 
procedures:  Physiological and self-report manifestations. JAP. 106, 15-25.
Fagerstrom, K. O. (1978). "Measuring degree of physical dependence to tobacco smoking with 
reference to individualization of treatment." Addict Behav 3(3-4): 235-241.
Fals-Stewart, W., O'Farrell, T. J., Freitas, T. T., McFarlin, S. K., Rutigliano, P., 2000. The Timeline 
followback reports of psychoactive substance use by drug-abusing patients: Psychometric 
properties. J. Consult. Clin. Psychol. 68, 134-144.
First, M., Gibbon, M., Spitzer, R., Williams, J. 1995. User's Guide to the structured clinical interview 
for DSM-IV axis disorders (SCID-I, Version 2.0)
Foa, E. and M. Kozak (1986). “Emotional processing of fear:  Exposure to corrective information.” 
Psychological Bulletin 99(1): 20-35.
Ford, M.M., Yoneyama, N., Strong, M.N., Fretwell, A., Tanchuck, M., Finn, D.A., 2008. Inhibition of 
5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J 
mice. Alcoholism, clinical and experimental research 32, 1408-1416.
Fox, H. C., K. I. Hong, K. M. Siedlarz, K. Bergquist, G. Anderson, M. J. Kreek and R. Sinha (2009). 
"Sex-specific dissociations in autonomic and HPA responses to stress and cues in alcohol-
dependent patients with cocaine abuse." Alcohol Alcohol 44(6): 575-585.
Girdler, S.S., Straneva, P.A., Light, K.C., Pedersen, C.A., Morrow, A.L., 2001. Allopregnanolone 
levels and reactivity to mental stress in premenstrual dysphoric disorder. Biological psychiatry 
49, 788-797.
Golden, C. J. (1976). "Identification of brain disorders by the Stroop Color and Word Test." J Clin 
Psychol 32(3): 654-658.
Goldstein, D. S., 1998. Catecholamines in the periphery.  Overview. Adv. Pharmacol. 42, 529-539.
Hall, S. M., Havassy, B. E., Wasserman, D. A., 1990. Commitment to abstinence and acute stress in 
relapse to alcohol, opiates, and nicotine. J. Consult. Clin. Psychol. 58, 175-181.
Hall, S. M., Havassy, B. E., Wasserman, D. A., 1991. Effects of commitment to abstinence, positive 
moods, stress, and coping on relapse to cocaine use. J. Consult. Clin. Psychol. 59, 526-532.
Haskel, D. H., Pugatch, D., & McNair, D. M. (1969). Time-limited psychotherapy for whom? 
Archives of General Psychiatry, 21(5), 546-552.
Herman, J.P., Mueller, N.K., Figueiredo, H., 2004. Role of GABA and glutamate circuitry in 
hypothalamo-pituitary-adrenocortical stress integration. Annals of the New York Academy of 
Sciences 1018, 35-45.
Higgins, S. T., A. J. Budney, W. K. Bickel, F. E. Foerg, R. Donham and G. J. Badger (1994). 
"Incentives improve outcome in outpatient behavioral treatment of cocaine dependence." Arch 
Gen Psychiatry 51(7): 568-576.
Hodgins, D. C., el-Guebaly, N., & Armstrong, S. (1995). Prospective and retrospective reports of 
mood states before relapse to substance use. Journal of Consulting & Clinical Psychology, 63(3), 
400-407.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 51 of 55
Holdstock, L., Penland, S.N., Morrow, A.L., de Wit, H., 2006. Moderate doses of ethanol fail to 
increase plasma levels of neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one-like 
immunoreactivity in healthy men and women. Psychopharmacology 186, 442-450.
Izard, C. (1972). Patterns of emotions:  A new analysis of anxiety and depression. New York: 
Academic Press.
Kirschbaum, C., S. Wust, et al., (1992). “Heritability of cortisol responses to h-CRH, ergometry, and 
psychological stress in humans.” Journal of Clinical Endocrinology and Metabolism 75: 1526-
1530.
Kranzler, H., Kadden, R., Babor, T., Tennen, H., & Rounsaville, B. (1996). Validity of the scid in 
substance abuse patients. Addiction, 91(6), 859-868.
Kranzler HR, Abu-Hasaballah K, Tennen H, Feinn R, Young K (2004) Using daily interactive voice 
response technology to measure drinking and related behaviors in a pharmacotherapy study. 
Alcohol Clin Exp Res. 28(7):1060-4. 
Lambert, J.J., Belelli, D., Harney, S.C., Peters, J.A., Frenguelli, B.G., 2001. Modulation of native and 
recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain 
research. Brain research reviews 37, 68-80.
Lang, P., D. Levin, et al., (1983). “Fear behavior, fear imagery, and the psychophysiology of emotion:  
The problem of affective response integration.” Journal of  Abnormal Psychology 92(3): 276-
306.
Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L., Paul, S.M., 1986. Steroid hormone 
metabolites are barbiturate-like modulators of the GABA receptor. Science 232, 1004-1007.
Margolin, A., Avants, S. K., & Kosten, T. R. (1994). Cue-elicited cocaine craving and autogenic 
relaxation:  Association with treatment outcome. Journal of Substance Abuse Treatment, 11(6), 
549-552.
Marlatt, G. A., & Gordon, J. R. (1985). Relapse prevention:  Maintenance strategies in the treatment of 
addictive behaviors. New York: Guilford Press.
Marx, C.E., Stevens, R.D., Shampine, L.J., Uzunova, V., Trost, W.T., Butterfield, M.I., Massing, 
M.W., Hamer, R.M., Morrow, A.L., Lieberman, J.A., 2006a. Neuroactive steroids are altered in 
schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. 
Neuropsychopharmacology 31, 1249-1263.
Marx, C.E., Trost, W.T., Shampine, L., Behm, F.M., Giordano, L.A., Massing, M.W., Rose, J.E., 
2006b. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. 
Psychopharmacology 186, 462-472.
Marx, C. E., R. S. Keefe, R. W. Buchanan, R. M. Hamer, J. D. Kilts, D. W. Bradford, J. L. Strauss, J. 
C. Naylor, V. M. Payne, J. A. Lieberman, A. J. Savitz, L. A. Leimone, L. Dunn, P. Porcu, A. L. 
Morrow and L. J. Shampine (2009). "Proof-of-concept trial with the neurosteroid pregnenolone 
targeting cognitive and negative symptoms in schizophrenia." Neuropsychopharmacology 34(8): 
1885-1903.
Marx, C.E., Lee, J., Subramaniam, M., Rapisarda, A., Bautista, D.C., Chan, E., Kilts, J.D., Buchanan, 
R.W., Wai, E.P., Verma, S., Sim, K., Hariram, J., Jacob, R., Keefe, R.S., Chong, S.A., 2014. 
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. 
Psychopharmacology (Berl) 231, 3647-3662.
Maude-Griffin, P. M., & Tiffany, S. T. (1996). The production of smoking urges through imagery:  
The impact of affect and smoking abstinence. Experimental & Clinical Psychopharmacology, 
4(2), 198-208.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 52 of 55
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., et al. (1992). The fifth 
edition of the addiction severity index. Journal of Substance Abuse Treatment, 9(3), 199-213.
McMahon, R. C., & Davidson, R. S. (1986). Patterns of stability and change in mood states of 
alcoholics in inpatient treatment. International Journal of the Addictions, 21(8), 923-927.
McNair, D., Lorr, M., & Droppleman, L. (1981). Manual of the profile of mood states. San Diego, 
California.
McNeil, D. W., Vrana, S. R., Melamed, B. G., Cuthbert, B. N., Lang, P. J., (1993). "Emotional 
imagery in simple and social phobia: Fear versus anxiety." JAP. 102, 212-225.
Mercer, D. E., & Woody, G. E. (1998). An individual drug counseling approach to treat cocaine 
addiction: The collaborative cocaine treatment study model (Manual 3). Bethesda, MD: National 
Institute on Drug Abuse.
Milivojevic, V., Kranzler, H.R., Gelernter, J., Burian, L., Covault, J., 2011. Variation in genes 
encoding the neuroactive steroid synthetic enzymes 5alpha-reductase type 1 and 3alpha-
reductase type 2 is associated with alcohol dependence. Alcoholism, clinical and experimental 
research 35, 946-952.
Milivojevic, V., Feinn, R., Kranzler, H.R., Covault, J., 2014. Variation in AKR1C3, which encodes the 
neuroactive steroid synthetic enzyme 3alpha-HSD type 2 (17beta-HSD type 5), moderates the 
subjective effects of alcohol. Psychopharmacology 231, 3597-3608.
Milivojevic, V., R. Sinha, P. T. Morgan, M. Sofuoglu and H. C. Fox (2014). "Effects of endogenous 
and exogenous progesterone on emotional intelligence in cocaine-dependent men and women 
who also abuse alcohol." Hum Psychopharmacol 29(6): 589-598.
Milivojevic, V., H. C. Fox, M. Sofuoglu, J. Covault and R. Sinha (2016). "Effects of progesterone 
stimulated allopregnanolone on craving and stress response in cocaine dependent men and 
women." Psychoneuroendocrinology 65: 44-53.
Miller, G., D. Levin, et al., (1987). “Individual differences in imagery and the psychophysiology of 
emotion.” Cognition and Emotion 1: 367-390.
Miller, W. R., & Del Boca, F. K. (1994). Measurement of drinking behavior using the form 90 family 
of instruments. Journal of Studies on Alcohol, 12 (Suppl.)), 112-118.
Miller, W., & Tonigan, J. (1996). The stages of change readiness and treatment eagerness scale 
(socrates). Psychology of Addictive Behavior, 10, 81-89.
Morrow, A.L., Janis, G.C., VanDoren, M.J., Matthews, D.B., Samson, H.H., Janak, P.H., Grant, K.A., 
1999. Neurosteroids mediate pharmacological effects of ethanol: a new mechanism of ethanol 
action? Alcoholism, clinical and experimental research 23, 1933-1940.
Morrow, A.L., VanDoren, M.J., Penland, S.N., Matthews, D.B., 2001. The role of GABAergic 
neuroactive steroids in ethanol action, tolerance and dependence. Brain research. Brain research 
reviews 37, 98-109.
Nyberg, S., Andersson, A., Zingmark, E., Wahlstrom, G., Backstrom, T., Sundstrom-Poromaa, I., 
2005. The effect of a low dose of alcohol on allopregnanolone serum concentrations across the 
menstrual cycle in women with severe premenstrual syndrome and controls. 
Psychoneuroendocrinology 30, 892-901.
O'Malley, S.S., Krishnan-Sarin, S., Farren, C., Sinha, R., Kreek, M.J. (2002). “Naltrexone decreases 
craving and alcohol self-administration in alcohol-dependent subjects and activates the 
hypothalamo-pituitary-adrenocortical axis.” Psychopharmacology. 164(2):239-40.
Orr, S., R. Pitman, et al., (1993). “Psychophysiological assessment of posttraumatic stress disorder 
imagery in world war II and korean combat veterans.” Journal of Abnomal Psychology 102(1): 
152-159.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 53 of 55
Parker, J. and N. Endler (1992). “Coping with coping assessment:  A critical review.” European 
Journal of Personality 6: 321-344.
Patton, J. H., M. S. Stanford and E. S. Barratt (1995). "Factor structure of the Barratt impulsiveness 
scale." J Clin Psychol 51(6): 768-774.
Payne, T. J., Rychtarik, P. G., Rappaport, N. B., Smith, P. O., Edscheit, M., Brown, T., et al. (1992). 
Reactivity to alcohol-relevant beverage and imaginal cues in alcoholics. Addictive Behaviors, 
17(3), 209-217.
Pierucci-Lagha, A., Covault, J., Feinn, R., Khisti, R.T., Morrow, A.L., Marx, C.E., Shampine, L.J., 
Kranzler, H.R., 2006. Subjective effects and changes in steroid hormone concentrations in 
humans following acute consumption of alcohol. Psychopharmacology 186, 451-461.
Pitman, R., S. Orr, et al., (1987). “Psychophysiologic assessment of posttraumatic stress disorder 
imagery in Vietnam Combat Veterans.” Arch Gen Psychistry 44: 970-975.
Porcu, P., Sogliano, C., Cinus, M., Purdy, R.H., Biggio, G., Concas, A., 2003. Nicotine-induced 
changes in cerebrocortical neuroactive steroids and plasma corticosterone concentrations in the 
rat. Pharmacology, biochemistry, and behavior 74, 683-690.
Prochaska, J. O., & DiClemente, C. C. (1982). Transtheoretical therapy: Toward a more integrative 
model of change. Psychotherapy: Theory, Research, & Practice, 19(3), 276-288.
Purdy, R.H., Morrow, A.L., Moore, P.H., Jr., Paul, S.M., 1991. Stress-induced elevations of gamma-
aminobutyric acid type A receptor-active steroids in the rat brain. Proceedings of the National 
Academy of Sciences of the United States of America 88, 4553-4557.
Rubonis, A. V., Colby, S. M., Monti, P. M., Rohsenow, D. J., Gulliver, S. B., & Sirota, A. D. (1994). 
Alcohol cue reactivity and mood induction in male and female alcoholics. Journal of Studies on 
Alcohol, 55(4), 487-494.
Sanna, E., Talani, G., Busonero, F., Pisu, M.G., Purdy, R.H., Serra, M., Biggio, G., 2004. Brain 
steroidogenesis mediates ethanol modulation of GABAA receptor activity in rat hippocampus. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 24, 6521-6530.
Sarkar, J., Wakefield, S., MacKenzie, G., Moss, S.J., Maguire, J., 2011. Neurosteroidogenesis is 
required for the physiological response to stress: role of neurosteroid-sensitive GABAA 
receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience 31, 
18198-18210.
Scheier, M. F. and C. S. Carver (1985). "Optimism, coping, and health: assessment and implications of 
generalized outcome expectancies." Health Psychol 4(3): 219-247.
Schwartz, G. and D. Weinberger (1980). “Patterns of emotional responses to affective situations:  
Relations among happiness, sadness, anger, fear, depression and anxiety.” Motivation and 
Emotion 4: 175-191.
Schwartz, G., D. Weinberger, et al., (1981). “Cardiovascular differentiation of happiness, sadness, 
anger, and fear following imagery and exercise.” psychosomatic Medicine 43: 343-364.
Shaham, Y., Stewart, J., (1995). "Stress reinstates heroin-seeking in drug-free animals: An effect 
mimicking heroin, not withdrawal." Psychopharmacology (Berl). 119, 334-341.
Shalev, A., S. Orr, et al., (1993). “Psychophysiologic Assessment of Traumatic Imagery in Israel 
Civilian Patients with posttraumatic stress disorder.” Am J Psychiatry 150(4): 620-624.
Sheehan, P. W. (1967). "Reliability of a short test of imagery." Percept Mot Skills 25(3): 744.
Silverman, K., S. T. Higgins, R. K. Brooner, I. D. Montoya, E. J. Cone, C. R. Schuster and K. L. 
Preston (1996). "Sustained cocaine abstinence in methadone maintenance patients through 
voucher-based reinforcement therapy." Arch Gen Psychiatry 53(5): 409-415.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 54 of 55
Simpson TL, Kivlahan DR, Bush KR, McFall ME (2005) Telephone self-monitoring among alcohol 
use disorder patients in early recovery: a randomized study of feasibility and measurement 
reactivity. Drug Alcohol Depend. 79(2):241-50. Epub 2005 Feb 25.
Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, 
Raskind M (2009). A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol 
dependence.  Alcohol Clin Exp Res. 33(2):255-63. 
Sinha, R., W. Lovallo, et al., (1992). “Cardiovascular differentiation of emotions.” Psychosomatic 
Medicine 54: 422-435.
Sinha, R. and O. Parsons (1996). “Multivariate response patterning of fear and anger.” Cognition and 
Emotion 10(2): 173-198.
Sinha, R., D. Catapano, et al., (1999a). “Stress-induced craving and stress response in cocaine 
dependent individuals.” Psychopharmacology 142: 343-351.
Sinha, R., O'Malley SS. (1999). Alcohol and craving: Findings from the clinic and laboratory. Alcohol 
and Alcoholism, 34, 223-230.
Sinha, R., T. Fuse, et al., (2000). “Psychological stress, drug-related cues and cocaine craving.” 
Psychopharmacology 152(2): 140-148.
Sinha, R. (2001b). “Manual for imagery script development procedures.” Unpublished manuscript.
Sinha, R., Talih, M., Malison, R., Anderson, G. A., Cooney, N., Kreek, M., (2003). "Hypothalamic-
pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug 
cue-induced cocaine craving states." Psychopharmacology (Berl). 170, 62-72.
Sobell, L. C., Sobell, M. B., Leo, G. I., & Cancilla, A. (1988). “Reliability of a timeline method: 
Assessing normal drinkers' reports of recent drinking and a comparative evaluation across 
several populations.” British Journal of Addiction, 83, 393-402.
Sobell, L. C., Brown, J., Leo, G. I., & Sobell, M. B. (1996). “The reliability of the Alcohol Timeline 
Followback when administered by telephone and by computer.” Drug and Alcohol Dependence. 
42, 49-54.
Sripada, R. K., C. E. Marx, A. P. King, J. C. Rampton, S. S. Ho and I. Liberzon (2013). 
"Allopregnanolone elevations following pregnenolone administration are associated with 
enhanced activation of emotion regulation neurocircuits." Biol Psychiatry 73(11): 1045-1053.
Tiffany, S. T. (1990). A cognitive model of drug urges and drug use behavior: Role of automatic and 
nonautomatic processes. Psychological Review, 97(2), 147-168.
Tiffany, S. T., & Drobes, D. J. (1990). Imagery and smoking urges: The manipulation of affective 
content. Addictive Behaviors, 15(6), 531-539.
Tiffany, S. T., Singleton, E., Haertzen, C. A., & Henningfield, J. E. (1993). The development of a 
cocaine craving questionnaire. Drug and Alcohol Dependence, 34, 19-28.
Torres, J.M., Ruiz, E., Ortega, E., 2001. Effects of CRH and ACTH administration on plasma and 
brain neurosteroid levels. Neurochemical research 26, 555-558.
Torres, J.M., Ortega, E., 2003. Alcohol intoxication increases allopregnanolone levels in female 
adolescent humans. Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 28, 1207-1209.
Torres, J.M., Ortega, E., 2004. Alcohol intoxication increases allopregnanolone levels in male 
adolescent humans. Psychopharmacology 172, 352-355.
Uzunova, V., Sampson, L., Uzunov, D.P., 2006. Relevance of endogenous 3alpha-reduced 
neurosteroids to depression and antidepressant action. Psychopharmacology 186, 351-361.
VanDoren, M.J., Matthews, D.B., Janis, G.C., Grobin, A.C., Devaud, L.L., Morrow, A.L., 2000. 
Neuroactive steroid 3alpha-hydroxy-5alpha-pregnan-20-one modulates electrophysiological and 
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023


APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023
HIC# 1603017466
March 2023                                                       Page 55 of 55
behavioral actions of ethanol. The Journal of neuroscience: the official journal of the Society for 
Neuroscience 20, 1982-1989.
Vallee, M., Vitiello, S., Bellocchio, L., Hebert-Chatelain, E., Monlezun, S., Martin-Garcia, E., 
Kasanetz, F., Baillie, G.L., Panin, F., Cathala, A., Roullot-Lacarriere, V., Fabre, S., Hurst, D.P., 
Lynch, D.L., Shore, D.M., Deroche-Gamonet, V., Spampinato, U., Revest, J.M., Maldonado, R., 
Reggio, P.H., Ross, R.A., Marsicano, G., Piazza, P.V., 2014. Pregnenolone can protect the brain 
from cannabis intoxication. Science 343, 94-98.
Wallace, B. C., (1989). "Psychological and environmental determinants of relapse in crack cocaine 
smokers." J. Subst. Abuse Treat. 6, 95-106.
White, M. A., B. L. Whisenhunt, D. A. Williamson, F. L. Greenway and R. G. Netemeyer (2002). 
"Development and validation of the food-craving inventory." Obes Res 10(2): 107-114.
White, M. A. and C. M. Grilo (2005). "Psychometric properties of the Food Craving Inventory among 
obese patients with binge eating disorder." Eat Behav 6(3): 239-245.
Zigmond A.S., Snaith R.P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 
67:361–70.
APPROVED BY THE YALE UNIVERSITY IRB 3/3/2023

ICF_001.pdf: 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 1 of 12
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A RESEARCH 
PROJECT
200 FR. 4 (2016-1) 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL
Study Title: The role of neuroactive steroids in stress, drug craving and drug use in cocaine use disorders
Principal Investigator: Verica Milivojevic, PhD, 2 Church Street South Suite 209, New Haven, CT 06519
Funding Source: National Institute of Health, NIDA
Invitation to Participate and Description of Project
You are invited to take part in a research study that will examine urges to use cocaine in women and men with 
the goal of  improving treatment for cocaine abuse. We hope in the future to develop better treatments to reduce 
cocaine craving and use. You have been asked to take part because we understand that you are seeking 
treatment for cocaine use disorder and are interested in participating in a research study examining cocaine 
craving and cocaine use. Approximately, 60 persons will be recruited for this study.
You are invited to participate in a research study to improve treatment for cocaine abuse. In order to decide 
whether or not you wish to be a part of this research study, you should know enough about its risks and benefits 
to make an informed decision.  This consent form gives you detailed information about the study, which a member 
of the research team will discuss with you.  This discussion should go over all aspects of this research: its purpose, 
the procedures that will be performed, any risks of the procedures, possible benefits and possible alternative 
treatments. Once you understand the study, you will be asked if you wish to participate; if so, you will be asked 
to sign this form.
The goal of this study is to look at how pregnenolone affects the body’s response to stressful situations, if it reduces 
cocaine craving, affects mood, and if there are any differences in response between men and women. You may or 
may not experience craving for cocaine or other drugs when you are in stressful, neutral or drug-related situations. 
We will check your craving and mood to see the effect that these situations may have on your cocaine craving. We 
are also trying to see if pregnenolone will reduce daily cocaine use. These findings may also help us understand the 
physical and mental effects of stress, so as to better understand the factors that lead to cocaine use and relapse.
Description of Procedures
If you agree to take part in this study, you will be admitted to the Clinical Neuroscience Research Unit (CNRU) 
or the “Unit” of the Connecticut Mental Health Center (CMHC) on 34 Park Street for inpatient research 
procedures. While on the CNRU, you will be offered 2 weeks of inpatient substance abuse treatment, which 
consists of daily standard individual and group drug counseling. You will then be offered 6 weeks of outpatient 
treatment with weekly standard individual drug counseling at the Yale Stress Center at 2 Church Street South, 
following your discharge from the CNRU. 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 2 of 12
You will participate in an initial screening and intake session, followed by physical examination and blood 
work to determine eligibility. The day after your admission to the CNRU, you will be randomly assigned to 
receive one of two doses of pregnenolone (300mg/day or 500mg/day) or placebo (a dummy pill that does not 
contain any medicine but is used for the purposes of providing a comparison in this study to the study 
medication). In week 2, there will be an experimental laboratory component that involves imagining your own 
stressful, relaxing and drug related situations for very brief 5-minute periods on separate days. Following the 
completion of the laboratory sessions, you will be discharged from the CNRU and continue your treatment at 
the Yale Stress Center with weekly appointments for the remainder of the study. You will also be provided with 
behavioral counseling and allowed to win monetary prizes for attending treatment at the Yale Stress Center. 
You will meet with a psychiatrist who will explain the risks and benefits associated with taking 
pregnenolone/placebo. If you are willing to participate in the study, you will be asked to sign this consent form after 
which you will be interviewed and be asked to complete some questionnaires.
Intake procedures:
If you agree to take part in this study, you will be asked to complete 2-3 intake appointments. Intake 
appointments take approximately 1.5 hours to complete and they will be conducted at the Yale Stress Center on 
2 Church Street South, New Haven, CT. During these appointments we will ask questions about your cocaine 
use, demographics and health history. You will also complete a physical examination and blood work to ensure 
that all inclusion and exclusion criteria for the study are met. You will be able to complete study assessments 
and clinical interviews via the phone or internet, if you wish so.  Study related blood work and urine samples 
will need to be done in-person, but you will also be able to visit a Quest Diagnostics location to provide a urine 
and blood sample instead of visiting the Center. If you decide to take part in this study, you must be free of major 
medical illnesses as determined by the physical examination, laboratory tests, urine analysis and EKG.  For 
women, you will be given a urine pregnancy screening test and scheduled to start pregnenolone/placebo 
medication in the week of the expected beginning of menstruation.
Inpatient Admission and Laboratory Sessions:
Upon enrollment into the study and for the experimental laboratory sessions, you will be admitted to the CNRU 
inpatient research unit. The day after your admission to the CNRU, you will be randomly assigned to either 
placebo or one of two doses (300mg/day; 500mg/day) of pregnenolone.  You will take pregnenolone or placebo 
twice daily as provided in weekly packs by the CNRU staff.  However, you will not know whether you are taking 
placebo or the pregnenolone.
The assignment to pregnenolone or placebo will be done by random selection, which means that it will be 
decided by the luck of the draw, and not selected deliberately because of any special characteristics or problems 
you have.  After taking the first dose of study medication, we will check your pulse, blood pressure and other 
physical and psychological symptoms. If you have any side effects from taking pregnenolone, you will meet with 
the research nurse or doctor who will check your symptoms.
We will also ask you to tell us about specific events from your personal life, events that were stressful for you and 
those that are associated with using drugs. Brief stories about these situations will be put together with you. These 
stories will be later played back to you during the laboratory sessions and you will be asked to briefly imagine these 
situations on different days. In addition to these stories we will ask you to select some situations that are neutral and 
relaxing from your own experiences. The neutral relaxing events that you select will also be described to you in a 
laboratory session and you will be asked briefly to imagine that situation as well. 
After completing the interview and testing sessions, you will have a training session. The research assistant will 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 3 of 12
meet with you and train you on how to generate and hold an image in your mind’s eye. We will guide you 
through imagining some common scenes such as reading a popular magazine and doing sit-ups in gym class, 
and coach you on how to focus and keep the image in your mind. 
We will also train you on how to get your body to relax by using relaxation procedures. The purpose of this 
training will be so you can clearly imagine the scenes that we will describe to you in the three imagery response 
laboratory sessions and can get yourself to become completely relaxed after imagining the scenes. In this 
session, we will once again describe the laboratory procedures to you and show you around the testing room. 
We will insert an intravenous (IV) catheter at this time so you can be familiar with having an IV in your arm. 
No blood samples will be drawn at this time.  In addition, we will provide you with clear instructions on how to 
fill out questionnaires on your feelings and craving. After this session, you will be able to return to your room or 
the common room at the CNRU.  The relaxation and imagery training session will last for one hour, while the 
full laboratory sessions will last for three hours scheduled from 2:00 PM to 5:00 PM for each of three days.
After the training session, you will take part in the three laboratory sessions on separate days. The laboratory 
sessions will begin at 2:00 PM at the CNRU. We will bring you to the testing room each morning of the 
laboratory session. When you come into the testing room with the research assistant we will first set you up to 
draw blood samples. An IV will be put into the vein in one of your arms so that we can draw blood at regular 
intervals. About four ounces of blood will be taken during each session, an amount less than a blood donation, 
which your body can easily tolerate. Over the three lab days, this will amount to 12 ounces of blood or the 
amount of a 12 ounce can of soda and somewhat less than then amount of blood drawn during a blood donation. 
While your body can tolerate this level of blood draw, you should not donate blood for a period of 8 weeks after 
you finish the study.  You also will not be admitted to the study if you have donated blood within a period 5 
weeks prior to admission to the research program.
The blood samples will be analyzed for naturally occurring chemicals that your body produces regularly.  At 
various times during the session we will place a small cotton ball in your mouth for you to hold on the side against 
your cheek for 2-3 minutes. This cotton ball will soak up saliva. We will collect the cotton ball in 3 minutes and 
place another one in your mouth every 10-15 minutes. Your saliva will then be analyzed for naturally occurring 
chemicals that your body produces regularly.
Next, we will attach a sensor (like a clothespin) to your finger to check your heart rate and place a blood pressure 
cuff on your arm to measure blood pressure. These are painless procedures. You will remain seated and relax for an 
additional 45 minutes. After this, we will place headphones and prepare you for the imagery session. After a brief 
relaxation period, you will be given instructions on the imagery task and you will then hear a story over the 
headphones. Your task will be to imagine yourself in the situation being described and relive it 'as if' it were 
happening to you at that moment. 
The story you will hear will be a description of one of your personal situations that you described to us during the 
intake or a description of the neutral situation that you selected. The order of stories in the three sessions will be 
selected randomly; you will not be told of the order of the stories presentation. After the imagery period, you will 
remain seated. From time to time, the nurse will enter to draw some blood and you will also be asked to make some 
ratings of your feelings and drug craving. You will also be asked to complete some brief mental tests. Following 
the imagery period, we will ask you to stay quietly in the testing room for an additional hour.  At various times 
during this period we will collect blood samples and ask you to make ratings of your feelings and craving.
During the course of the imagery session you may have some drug craving and changes in feelings due to your 
recall of personal events that were stressful or drug-related. Each laboratory imagery session will last for about 
three hours. You will be given brief rest periods if you so desire. Should you feel anxious or unduly uncomfortable 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 4 of 12
at any time during the session, you may ask that the session be stopped.  At the end of the laboratory session, the IV 
and the sensors will be removed, and we will give you relaxation instructions to help you reduce your craving and 
bring yourself into a relaxed mood. Once you are returned to your original mood state, the session will be over. 
You will be given a snack and will be finished with the session for the day. The same procedures will be done each 
day for the three laboratory imagery sessions.
At the end of all three laboratory sessions, you will be discharged from the CNRU and transition into an 
outpatient study phase of the study at the Yale Stress Center for the remainder of the 8 weeks. 
Outpatient Study Phase:
Upon completion of the laboratory sessions, you will continue to take the same dose of pregnenolone or placebo 
and be seen at the Yale Stress Center twice weekly. You may also complete study assessments, clinical 
interviews, medication compliance procedures and counseling sessions remotely via phone or Internet, and only 
come in once a week for blood draws and urine sample collection.
You will be seen at the at the Yale Stress Center (YSC), on 2 Church Street South (YSC) twice a week with 1x per 
week standard individual drug counseling with a psychologist or qualified counselor.  The purpose of this phase is 
to assist you in reducing your cocaine use and continue your recovery from cocaine use.  During the outpatient t 
phase of the study, we will ask you about your cocaine and drug use and other psychological and physical 
problems that you may have now or in the past. Study staff will provide you with weekly medication packs.  We 
will also ask you to complete several paper and pencil tests about your drug use and problems you have.  You will 
also take some mental tests.
We will communicate with you using the smartphone using an application called MetricWire and eMocha. The 
apps will remind you daily to take your study medication, and make ratings on your mood and, craving, and tell us 
about your cocaine use. To check that you are taking your study medication, we will be collecting urines, and doing 
a blood draw at weeks 2, 5, and 7. The study medication will have riboflavin added as a marker. Riboflavin 
produces a bright yellow discoloration of the urine when the medication is taken 2 to 8 hours prior, so study staff 
will be able to visually inspect whether you have taken the medication. You will also use the eMocha app to video-
record yourself taking your medication. You will receive random prompts to complete a brief 1-minute survey of 
questions and a third 5-10 minute survey to be completed at night before bedtime. The surveys are set up with 
standard automated questions and prompts and you will use the phone key pad to answer the prompts. All data will 
be encrypted and sent to a secure server where data is identified by subject ID only.  You will be trained to use the 
phones in this way at the start of the study and if you don’t have a smartphone one will be provided to you at no 
cost for the duration of the study. 
Each time that you visit the clinic (2x per week), we will obtain a urine sample for drugs and take a sample of your 
breath by asking you to blow into a breath machine or breathalyzer to see if you have recently consumed alcohol. 
You may also visit a Quest Diagnostics location to provide a urine and blood sample instead of visiting the Center.
Blood Sampling for Genetic Studies:
During the laboratory session 1, the nurse will take a sample of your blood for purposes of understanding 
genetic factors that may influence the way you behave / feel in response to stress. 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 5 of 12
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. 
This Web site will not include information that can identify you. At most, the Web site will include a summary 
of the results. You can search this Web site at any time.
You will be told of any significant new findings that are developed during the course of your participation in 
this study that may affect your willingness to continue to participate.
Optional Specimens for Future Storage/Genetic Testing
You are invited to allow some of your samples (called specimens) and related information to be stored (banked) 
for future research for purposes of understanding genetic factors that may influence the way you behave / feel in 
response to stress. This may help researchers in the future learn more about how to prevent, find and treat 
addiction and stress related health outcomes.
Your specimens will be stored for an unlimited time, and may be used to make a cell line that will live 
indefinitely.  Future research may look at your genes, which are the units of inheritance that are passed down 
from generation to generation.  Genes are responsible for many things about you such as eye color, hair color, 
blood type and hundreds of other traits.  Future genetic analysis may possibly include finding out the details of 
how your DNA is put together, such as whole exome or genome sequencing, or genome wide association 
studies (that is, looking at genes other than those associated with a specific disease).  
When your specimens and information are stored, we are careful to try to protect your identity from discovery 
by others.  Your samples and information will receive a unique code.  Other researchers will only receive coded 
samples and information, and will not be able to link the code to you.  Strict security safeguards are in place to 
reduce the chance of misuse or unplanned release of information.
Using your specimens for research will probably not help you.  We do hope the research results will help people 
in the future.
There is a risk that your information could be misused, for example by associating your personal information 
with genetic testing results.    The chance of this happening is very small.  We have protections in place to lower 
this risk, such as assigning a unique code to you, and keeping your personal information separate from this code 
in locked cabinets and also protecting all electronic data with a password.  There can also be a risk in 
uncovering genetic information.  New health information about inherited traits that might affect you or your 
blood relatives could be found during a research study.  Very rarely, health or genetic information could be 
misused by employers, health insurance companies, and others.  There is a federal law called the Genetic 
Information Nondiscrimination Act (GINA) that, in general, makes it illegal for health insurance companies, 
group health plans, and most employers (except those with fewer than 15 employees) to discriminate against 
you based on your genetic information.  However, it does not protect you against discrimination by companies 
that sell life insurance, disability insurance, or long-term care insurance.
Your specimens and information will only be used for research and will not be sold.  There is a possibility that 
this research may lead to development of products that will be commercialized.  If this happens, there is no plan 
to share any financial gain with you.
Research results will not be returned to you or your doctor.  If research results are published, your name and 
other personal information will not be given.
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 6 of 12
The choice to take part is up to you.  You may choose not to let us store and use your samples, and your care 
will not be affected by this decision.  If you decide that your samples can be kept, you may change your mind at 
any time.  Contact the study staff by phone or mail at (203) 737-3398, 2 Church Street South, New Haven CT 
06519 to let them know you do not want your samples used any longer.  Your samples will be made anonymous 
by destroying the code that’s linking them to you). 
 
I agree to allow my samples and information to be stored and used for future research as described above: 
(initial your choice)
_____YES
______No
Risks and Inconveniences
The main risks that might occur if you decide to participate in this study have to do with taking pregnenolone, the 
laboratory procedures, and the collection of genetic information. These are explained below:
i. Pregnenolone: Pregnenolone is a naturally occurring hormone and is well tolerated. It is sold over the 
counter as a dietary supplement. While controlled studies report minimal to no side effects, rare possible side 
effects of mild restlessness, acne, hair loss, hair growth on the face (in women), aggressiveness, irritability, 
and increased levels of estrogen have been reported anecdotally; and Pregnenolone may affect other hormones 
such as progesterone, estrogen, testosterone and/or DHEA, but clinical research studies have used 
pregnenolone in psychiatric patients and healthy individuals without any side effects.
ii. Intravenous (IV): When an intravenous catheter is started, there is some risk that you may develop a bruise or 
bleeding where the IV enters the vein. Usually these go away in several days without any treatment. On rare 
occasions, dizziness, fainting, blood clot or infection may occur.
iii. Drawing of Blood: 
A total amount of 537 mL of whole blood will be drawn throughout the entire study.  This is close to a regular 
blood donation. People who are in good health are not usually affected by this kind of blood loss. However, to be 
safe, you should not donate blood for at least 8 weeks after the three laboratory sessions.  
iv. The imagery procedures: The imagery task involves reliving a personal stressful event, a neutral event and a 
personal event associated with drug use. These can be anxiety provoking at the time of the task and may also lead 
to drug craving. Our previous experience has shown that once the task is over, there is very little anxiety that carries 
over, and the craving also decreases, so there is only minimal risk. During these imagery periods you may 
experience strong feelings and we will provide you with relaxation instructions to help you return to a relaxed state.  
v. Placement of a sterilized cotton ball in your mouth may be an inconvenience. Our previous experience with this 
method is that once you become familiar with the cotton ball in your mouth you will become accustomed to it and 
will feel minimal discomfort.
vi. Genetic Information: Under some circumstances, it can be a risk for genetic information about you to be 
known.  Variation in some genes is known to be directly related to risk for certain illnesses. Other genes we will 
be studying in your DNA may be shown at some point in the future to be related to illness. Since the results of 
these genetic tests may allow prediction of risk of illness in some cases, we will keep the results confidential.  
We will not make any of our laboratory results available to you, nor will we add them to your medical record.  
(If you want to know your risk for genetic diseases, we will refer you to a genetic counselor.)  We hope that this 
will prevent any information that could cause you trouble in the future (for example, by making it difficult for 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 7 of 12
you to obtain health or life insurance, or employment or educational opportunities) from becoming known to 
anyone other than the scientists working on this study.  We believe that the chance of this information becoming 
known to others in such a way that it would be harmful to you is very, very low. As identified above, there is a 
federal law called the Genetic Information Nondiscrimination Act (GINA) that, in general, makes it illegal for 
health insurance companies, group health plans, and most employers, except those with fewer than 15 
employees, to discriminate against you based on your genetic information.  However, it does not protect you 
against discrimination by companies that sell life insurance, disability insurance, or long-term care insurance. 
Even if the genetic information we collected about you did become known to a third party such as an insurer, it 
is unlikely that, in most cases, this particular information could be used to harm you economically.   
vii. Risk of breach of confidentiality: It is possible that someone unauthorized may gain access and see your 
private information. We will make every effort to keep your data safe and private. For more information about 
how your data is protected, check the “Confidentiality and Privacy“ paragraph.
Benefits
There are no known benefits to you at this time.  There are benefits to society, which would result from increased 
knowledge about new treatments for cocaine addiction. 
Economic Considerations
We will pay you $20 for the first intake interview session, $30 for the second, and $20 for the third intake 
session. You will receive a $50 bonus for the inpatient admission, and $100 for each of the 3 laboratory 
sessions. You will also be paid a $50 bonus for completing all components of the laboratory sessions. 
Therefore, for completion of the laboratory phase, you will receive a total of $470.
To assist you in recovery during the outpatient phase, you will earn chances to win a prize ranging from 0 to $100 
for each scheduled appointment that you keep. You will earn a chance to draw a prize, regardless of whether the 
urine sample you provide is clean or not. For every thrice/weekly appointment you attend, the chance to draw a 
prize from a fish bowl increases by one. The fish bowl prizes are valued at 0, $1, $5, $20, or $100. Failure to keep 
your scheduled appointment, or failure to take your study medication will reset the number of draws to one. A flat 
$20 payment for the completion of weekly appointments may also be used instead of the fish bowl.
In addition, for your participation in smartphone reminders you will be reimbursed at $2 a day, with a $6 bonus 
for completing all 7 days, hence a possible total of $20 a week, for the duration of the outpatient phase. In 
addition, you will receive $20 for week 5, and a $20 bonus for completing the entire 8 weeks of study. You will 
also receive $25 per week for using the eMocha smartphone App for taking the study medication. Therefore, the 
total that you may be reimbursed if you complete all aspects of the study and the follow-up interviews will be $830 
plus the various amounts won for keeping appointments throughout the study.
We will use a Bank of America pre-paid debit card to provide the payment for taking part in the study.  We will 
have to share your name, address, and telephone number with Bank of America for ePayments. You will receive 
a card in the mail with the first payment. You will need to activate the card over the phone. Each additional 
payment will be automatically added to your card. 
According to the requirements of the Internal Revenue Service (IRS), payments that are made to you as a result 
of your participation in this study may be considered taxable income. We will need your social security number 
for reporting of the study payments made to you. You are responsible for paying state, federal, or other taxes for 
the payments you receive for being in this study.  Taxes are not withheld from your payments.
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 8 of 12
Treatment Alternatives/Alternatives
You do not need to participate in this study in order to receive treatment for substance dependence such as 
counseling, group therapy, and psychotherapy. 
Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain confidential and will be 
disclosed only with your permission or as permitted by U.S. or State law.  We will make every effort to ensure 
your confidentiality.  In all records of the study you will be identified only by a number. All research materials 
with personal information will be stored in locked cabinets. All data that is stored on a computer will be password 
protected. When the results of the research are published or discussed in conferences, no information will be 
included that would reveal your identity unless your specific consent for this activity is obtained.  
We understand that information about you obtained in connection with your health is personal, and we are 
committed to protecting the privacy of that at information.  If you decide to be in this study, the researcher will 
get information that identifies you and your personal health information.  This may include information that might 
directly identify you, such as your name, birthdate, and address. This information will be de-identified at the 
earliest reasonable time after we receive it, meaning we will replace your identifying information with a code that 
does not directly identify you. The principal investigator will keep a link that identifies you to your coded 
information, and this link will be kept secure and available only to the PI or selected members of the research 
team. Any information that can identify you will remain confidential.  All research materials with personal 
information will be stored in locked cabinets. All data that is stored on a computer will be password protected. 
The research team will only give this coded information to others to carry out this research study. The link to your 
personal information will be kept for until the study is closed, after which time the link will be destroyed and the 
data will become anonymous. The data will be kept in this anonymous form. 
The information about your health that will be collected in this study includes
Research study records
Medical and laboratory records of only those services provided in connection with this Study.  
Records about phone calls made as part of this research
Records about your study visits
Medical information obtained during this research regarding sexually transmitted and other reportable 
infectious diseases, physical exam results, laboratory, and other test results
Questionnaires, the use of illegal drugs and illegal behavior
Records about any study drug you received
Information about you and your health which might identify you may be used by or given to: 

National Institute of Health (NIH)

Representatives from Yale University, the Yale Human Research Protection Program and the Yale 
Human Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects), who are responsible for ensuring research compliance.  These individuals are required 
to keep all information confidential. 

The Principal Investigator, Verica Milivojevic, PhD

Governmental agencies to whom certain diseases (reportable diseases) must be reported

Health care providers who provide services to you in connection with this study.

Study Coordinator and Members of the Research Team 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 9 of 12

Data Safety Monitor

The U.S. Department of Health and Human Services (DHHS) agencies

The U.S. Food and Drug Administration (FDA)
To further protect your privacy, we have obtained a Certificate of Confidentiality (CoC) from the National 
Institute on Drug Abuse (NIDA). With this Certificate, the study investigators and anyone else involved in the 
project cannot be forced to disclose any information about you, such as your name, information regarding your 
participation in this research, urinalysis results, or other information that you provide to us as part of this research, 
to anyone, including the courts.  
You should understand that a Certificate of Confidentiality does not prevent you or a member of your family from 
voluntarily releasing information about yourself or your involvement in this research. If an insurer, employer, or 
other person obtains your written consent to receive research information, then the researchers may not use the 
Certificate to withhold that information. We may release identifying information in some circumstances, however.  
The protection offered by the CoC does not stop us from voluntarily reporting information about suspected or 
known sexual, physical, or other abuse of a child or older person, or threats of violence to self or others. If any 
member of the research team is given such information, he or she will make a report to the appropriate authorities.  
We may also disclose medical information in cases of medical necessity, or take steps (including notifying 
authorities) to protect you from serious harm, including child abuse. The protection offered by the CoC does not 
stop us from voluntarily reporting information about suspected or known sexual, physical, or other abuse of a 
child or older person, or threats of violence to self or others. If any member of the research team is given such 
information, he or she will make a report to the appropriate authorities.
The Certificate cannot be used to resist a demand for information from personnel of the United States Government 
that is used for auditing or evaluation of federally funded projects or for information that must be disclosed in 
order to meet the requirements of the federal Food and Drug Administration (FDA). Also, because this research 
may be sponsored by NIDA, staff from that and other Department of Health and Human Services agencies may 
review records that identify you for audit or program evaluation. They, too, will protect your privacy. 
If you decide to be in this study, and you will be visiting the Connecticut Mental Health Center (CMHC) as 
part of your study procedures, some information about your participation in this research study will become 
part of your CMHC medical record that identifies you. If you do not already have a medical record at CMHC, 
one will be made for your visit. The information that will be entered into your medical record will include the 
following: your social security number, name, address, phone number, and physical exam results. A Certificate 
of Confidentiality (CoC) offers protection against compelled identification of research participants by name or 
other identifying information in any legal proceeding.
By signing this form, you authorize the use and/or disclosure of the information described above for this 
research study.  The purpose for the uses and disclosures you are authorizing is to ensure that the information 
relating to this research is available to all parties who may need it for research purposes.
All health care providers subject to HIPAA (Health Insurance Portability and Accountability Act) are required 
to protect the privacy of your information.  The research staff at the Yale School of Medicine, Yale-New Haven 
Hospital and the Connecticut Mental Health Center are required to comply with HIPAA and to ensure the 
confidentiality of your information.  Some of the individuals or agencies listed above may not be subject to 
HIPAA and therefore may not be required to provide the same type of confidentiality protection. They could 
use or disclose your information in ways not mentioned in this form.  However to better protect your health 
information, agreements are in place with these individuals and/or companies that require that they keep your 
information confidential. 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 10 of 12
You have the right to review and copy your health information in your medical record in accordance with 
institutional medical records policies. However, by deciding to take part in a single or double blinded treatment 
study and sign this permission form, you will not be allowed to look at or copy your study related information 
until after the research is completed.  
This authorization to use and disclose your health information collected during your participation in this study 
will never expire.
In Case of Injury
If you are injured while on study, seek treatment and contact the study doctor as soon as you are able.  
The Yale School of Medicine does not provide funds for the treatment of research-related injury.  If you are 
injured as a result of your participation in this study, treatment will be provided.  You or your insurance carrier 
will be expected to pay the costs of this treatment.  No additional financial compensation for injury or lost wages 
is available.
You do not give up any of your legal rights by signing this form.
Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this study.   Refusing to 
participate will involve no penalty or loss of benefits to which you are otherwise entitled (such as your health 
care outside the study, the payment for your health care, and your health care benefits).  However, you will not 
be able to enroll in this research study and will not receive study procedures as a study participant if you do not 
allow use of your information as part of this study.
Withdrawing From the Study
If you do become a subject, you are free to stop and withdraw from this study at any time during its course. 
To withdraw from the study, you can call a member of the research team at any time and tell them that you no 
longer want to take part.  This will cancel any future appointments. The researchers may withdraw you from 
participating in the research if necessary, for example you develop serious side effects or for non-compliance.
Withdrawing from the study will involve no penalty or loss of benefits to which you are otherwise entitled.  It 
will not harm your relationship with your own doctors or with the Yale Stress Center.
Withdrawing Your Authorization to Use and Disclose Your Health Information
You may withdraw or take away your permission to use and disclose your health information at any time. You 
may withdraw your permission by telling the study staff or by writing to Dr. Verica Milivojevic, 2 Church 
Street South, Suite 209 at the Yale Stress Center, New Haven CT 06519.
 If you withdraw your permission, you will not be able to stay in this study.
When you withdraw your permission, no new health information identifying you will be gathered after that date.  
Information that has already been gathered may still be used and given to others until the end of the research 
study, as necessary to insure the integrity of the study and/or study oversight.  If you withdraw from the study, all 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 11 of 12
collected blood samples will be stripped of all identifiers (anonymized) including your study ID number and we 
will continue to use them.
Questions
We have used some technical terms in this form.  Please feel free to ask about anything you don't 
understand and to consider this research and the consent form carefully – as long as you feel is necessary – before 
you make a decision.
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021


APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021
 HIC#: 1603017466
October 2021                                                                           Page 12 of 12
Authorization and Permission
I have read (or someone has read to me) this form and have decided to participate in the project described above.  
Its general purposes, the particulars of my involvement and possible hazards and inconveniences have been 
explained to my satisfaction.  My signature also indicates that I have received a copy of this consent form.
By signing this form, I give permission to the researchers to use [and give out] information about me for the 
purposes described in this form.  By refusing to give permission, I understand that I will not be able to be in this 
research. 
Name of Subject:_____________________________
                        
Signature:___________________________________
Date:______________________________________
___________________________________________
___________________
Signature of Principal Investigator
Date
                                      or
___________________________________________
___________________
Signature of Person Obtaining Consent
Date
If after you have signed this form you have any questions about your privacy rights, please contact the Yale 
Privacy Officer at 203/432-5919.
If you have further questions about this project or if you have a research-related problem, you may contact the 
Principal Investigator, Dr. Verica Milivojevic at (203) 737-1176.  If you would like to talk with someone other 
than the researchers to discuss problems, concerns, and questions you may have concerning this research, or to 
discuss your rights as a research subject, you may contact the Yale Human Investigation Committee at (203) 
785-4688. 
APPROVED BY THE YALE UNIVERSITY IRB 11/10/2021